false
--12-31
0001724979
0001724979
2024-01-26
2024-01-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 26, 2024
RAIN
ONCOLOGY INC.
(Exact
name of registrant as specified in its charter)
Delaware |
001-40356 |
82-1130967 |
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
8000 Jarvis Avenue, Suite 204 |
|
Newark, California |
94560 |
(Address
of Principal Executive Offices) |
(Zip
Code) |
|
|
Registrant’s telephone number, including area code: (510) 953-5559
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
Common Stock, $0.001 par value per share |
RAIN |
The Nasdaq Global Select Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.01. Completion of Acquisition or Disposition
of Assets.
As previously
disclosed by Rain Oncology Inc. (the “Company” or “Rain”) in the Company’s Current Report on Form 8-K filed
with the Securities and Exchange Commission (the “SEC”) on December 14, 2023, the Company entered into an Agreement and Plan
of Merger (the “Merger Agreement”) with Pathos AI, Inc., a Delaware corporation (“Parent”), and WK Merger Sub,
Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), dated as of December 13, 2023.
Pursuant to the Merger Agreement, and upon the terms
and subject to the conditions thereof, on January 26, 2024, Merger Sub completed a tender offer to purchase all of the Company’s
outstanding shares of common stock, par value $0.001 per share (the “Shares”), in exchange for (i) $1.16
in cash per Share (the “Cash Consideration”), plus (ii) one contingent value right per Share (each, a “CVR”),
which CVR represents the right to receive potential payments pursuant to the terms and subject to the conditions of the contingent value
rights agreement (the “CVR Agreement”), dated January 26, 2024, by and among Parent, Merger Sub, Equiniti Trust Company, LLC,
a New York limited liability trust company and Fortis Advisors LLC, a Delaware limited liability company (the Cash Consideration plus
one CVR, collectively, the “Offer Price”), all subject to and in accordance with the terms and conditions set forth in the
Offer to Purchase, dated December 27, 2023 (as amended or supplemented from time to time, the “Offer to Purchase”), and in
the related Letter of Transmittal (as amended or supplemented from time to time, the “Letter of Transmittal,” which, together
with the Offer to Purchase, as each may have been amended or supplemented, constituted the “Offer”).
The foregoing description of the CVR Agreement does
not purport to be complete and is qualified in its entirety by reference to the full text of the CVR Agreement, a copy of which is filed
as Exhibit 2.2 hereto, and is incorporated herein by reference.
The Offer expired one minute after 11:59 P.M., Eastern
Time, on Thursday, January 25, 2024. According to Equiniti Trust Company, LLC, the depositary for the Offer, 28,031,182
Shares were validly tendered and not validly withdrawn, representing approximately 77%
of the aggregate number of then issued and outstanding Shares. The number of Shares tendered satisfied the Minimum Condition (as defined
in the Merger Agreement). All other conditions to the Offer were satisfied and Merger Sub accepted for payment all Shares validly tendered
(and not validly withdrawn) prior to the expiration of the Offer.
Following the consummation of the Offer, the remaining
conditions to the Merger set forth in the Merger Agreement were satisfied, and on January 26, 2024, Merger Sub merged with and into the
Company (the “Merger”), the separate corporate existence of Merger Sub ceased and the Company continued as the surviving corporation
in the Merger (the “Surviving Corporation”) and a wholly owned subsidiary of Parent. The Merger was completed pursuant to
Section 251(h) of the DGCL, with no stockholder vote required. At the effective time of the Merger (the “Effective Time”),
each outstanding Share (other than (1) Shares owned or held in the Company’s treasury immediately prior to the Effective Time, (2)
Shares owned directly or indirectly by Parent or Merger Sub immediately prior to the Effective Time and (3) Shares held by any Rain stockholder
who was entitled to and properly demanded appraisal of such Shares in accordance with Section 262 of the DGCL) was converted automatically
into the right to receive the Offer Price from Merger Sub.
Pursuant to
the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each
option to purchase Shares from the Company under the Company’s Amended and Restated 2018 Stock Option/Stock Issuance Plan or 2021
Equity Incentive Plan, pursuant to an inducement award, or otherwise (together, the “Company Stock Plans”) were
cancelled for no consideration; and each restricted stock unit settleable in Shares granted under the Company Stock Plans (each, a “Company
RSU”) that was outstanding and unvested as of immediately prior to the Effective Time vested in full and was automatically cancelled
and converted into the right to receive (i) an amount in cash equal to the product of (A) the total number of Shares then underlying such
Company RSU multiplied by (B) the Cash Consideration, without any interest thereon and subject to applicable withholding and (ii) one
(1) CVR for each Share subject thereto.
The foregoing description of the Merger Agreement
and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Merger
Agreement, a copy of which is filed as Exhibit 2.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 3.01. Notice of Delisting or Failure to Satisfy
a Continued Listing Rule or Standard; Transfer of Listing.
The information
set forth under Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.01.
In connection with the consummation of the Offer and
the Merger, the Company (i) notified The Nasdaq Global Select Market LLC (“Nasdaq”) of the consummation of the Merger and
(ii) requested that Nasdaq (A) suspend trading of the Shares effective before the opening of trading on January 26, 2024 and (B) file
with the SEC a Notification of Removal from Listing and/or Registration on Form 25 to effect the delisting of all Shares from Nasdaq and
the deregistration of such Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
In addition, the Company intends to file a Certification and Notice of Termination of Registration on Form 15 with the SEC requesting
the termination of registration of the Shares under Section 12(g) of the Exchange Act and the suspension of reporting obligations under
Section 13 and 15(d) of the Exchange Act with respect to the Shares.
Item 3.03. Material Modification to Rights of Security
Holders.
The information
set forth under Items 2.01, 3.01, 5.01, and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.
Item 5.01. Changes in Control of Registrant.
The information
set forth under Items 2.01, 5.02, and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01.
As a result
of the consummation of the Offer and the Merger, there was a change in control of the Company, and the Company became a wholly owned subsidiary
of Parent.
Item 5.02. Departures
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Pursuant to the terms of the Merger Agreement, at
the Effective Time, each of Avanish Vellanki, Franklin Berger, Aaron Davis, Gorjan Hrustanovic, Tran Nguyen, Peter Radovich and Stefani
A. Wolff resigned from the board of directors of the Company. These resignations were tendered in connection with the Merger and not as
a result of any disagreements between the Company and the resigning individuals on any matters related to the Company’s operations,
policies, or practices.
Following the Merger and pursuant to the terms of
the Merger Agreement, at the Effective Time, the directors and officers of Merger Sub immediately prior to the Effective Time became the
directors and officers of the Surviving Corporation. The directors of Merger Sub immediately prior to the Effective Time were Ryan Fukushima
and Eric Lefkofsky. The executive officers of Merger Sub immediately prior to the Effective Time were Ryan Fukushima, serving as Chief
Executive Officer, and Zack Malkin, serving as Chief Financial Officer and Secretary.
Information
regarding the new directors and executive officers of the Company has been previously disclosed in Schedule A to the Offer to Purchase
filed as Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO filed by Parent and Merger Sub with the SEC on December 27, 2023,
as subsequently amended, which is incorporated herein by reference.
Item 5.03. Amendments to Articles of Incorporation
or Bylaws; Change in Fiscal Year.
Pursuant to
the terms of the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation and bylaws were each amended
and restated in their entirety as set forth on Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated
herein by reference.
Item 9.01. Exhibits
Exhibit No. |
|
Description |
2.1* |
|
Agreement and Plan of Merger, dated December 13, 2023, by and among Rain, Parent and Merger Sub (incorporated herein by reference to Exhibit 2.1 to Form 8-K filed by Rain on December 14, 2023). |
2.2*# |
|
Contingent Value Rights Agreement, dates January 26, 2024, by and among Parent, Merger Sub, Equiniti Trust Company, LLC and Fortis Advisors LLC. |
3.1# |
|
Fifth Amended and Restated Certificate of Incorporation of Rain Oncology Inc. |
3.2# |
|
Amended and Restated Bylaws of Rain Oncology Inc. |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* Schedules have been omitted pursuant to Item 601(b)(2) of Regulation
S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC; provided, however,
that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934 for
any schedules so furnished.
# Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
RAIN ONCOLOGY INC. |
|
|
|
Date: January 26, 2024 |
By: |
/s/ Ryan Fukushima |
|
|
Ryan Fukushima |
|
|
Chief Executive Officer |
RAIN ONCOLOGY INC. 8-K
Exhibit
2.2
CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS
AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK
“[***]”.
Execution
Version
CONTINGENT
VALUE RIGHTS AGREEMENT
THIS
CONTINGENT VALUE RIGHTS AGREEMENT, dated as of January 26, 2024 (this “Agreement”), is entered into by and between
Pathos AI, Inc., a Delaware corporation (the “Parent”), WK Merger Sub, Inc., a Delaware corporation and a wholly owned
Subsidiary of Parent (the “Purchaser”), Equiniti Trust Company, LLC, a New York limited liability trust company (the
“Rights Agent”), and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the initial
representative, agent and attorney in-fact of the Holders (the “Representative”).
RECITALS
WHEREAS,
Parent, Purchaser, and Rain Oncology Inc., a Delaware corporation (“Rain”), have entered into an Agreement and Plan
of Merger, dated as of December 13, 2023 (the “Merger Agreement”), pursuant to which Purchaser will merge with and
into Rain (the “Merger”), with Rain surviving the Merger as a wholly owned Subsidiary of Parent;
WHEREAS,
pursuant to the Merger Agreement, and in accordance with the terms and conditions thereof, Purchaser shall deliver CVRs to holders of
outstanding Rain Common Stock and Rain RSUs (as such terms are defined herein and, in each case, subject to certain exceptions) (collectively,
the “Initial Holders”) pursuant to the terms and subject to the conditions hereinafter described;
WHEREAS,
the CVRs are an integral part of the consideration to be received by the Initial Holders in the Merger;
WHEREAS,
Parent desires that the Rights Agent act as its agent for the purposes of effecting the distribution of the CVRs to the Initial Holders
and performing the other services described in this Agreement; and
WHEREAS,
the Initial Holders desire that the Representative act as their agent for the purposes of accomplishing the intent and implementing the
provisions of this Agreement and facilitating the consummation of the transactions contemplated hereby and performing the other services
described in this Agreement.
NOW,
THEREFORE, in consideration of the foregoing and the consummation of the transactions referred to above, the parties agree, for the equal
and proportionate benefit of all Holders (as defined herein), as follows:
ARTICLE
I
DEFINITIONS: CERTAIN RULES OF CONSTRUCTION
Section
1.1 Definitions. Capitalized terms used but not otherwise defined herein have the meanings ascribed thereto in the Merger Agreement.
As used in this Agreement, the following terms will have the following meanings:
“Acting
Holders” means, at the time of determination, Holders of not less than thirty percent (30%) of outstanding CVRs, as set forth
in the CVR Register.
“Affiliate”
of any particular Person means any other Person controlling, controlled by or under common control with such particular Person. For the
purposes of this definition, “controlling,” “controlled” and “control” mean the possession, directly
or indirectly, of the power to direct the management and policies of a Person whether through the ownership of voting securities, contract
or otherwise.
“Assignee”
has the meaning set forth in Section 6.3.
“Business
Day” means a day, other than a Saturday, Sunday or public holiday, on which clearing banks are open for non-automated commercial
business in New York, New York.
“Cash
CVR Payment Expiration Date” means the latest to occur of (a) 12 months following the Closing Date and (b) the delivery by
the Rights Agent to each Holder of all potential CVR Payment Amounts (if any) required to be paid under the terms of this Agreement with
respect to any Cash CVR Payments.
“Change
of Control” means (a) a sale or other disposition of all or substantially all of the assets of Purchaser on a consolidated
basis (other than to any Subsidiary (direct or indirect) of Parent), (b) a merger or consolidation involving Purchaser in which Purchaser
is not the surviving entity if the stockholders of Purchaser immediately prior to such transaction own less than 50% of the surviving
entity’s voting power immediately after the transaction, and (c) any other transaction involving Purchaser in which Purchaser is
the surviving or continuing entity but in which the stockholders of Purchaser immediately prior to such transaction own less than 50%
of Purchaser’s voting power immediately after the transaction.
“Closing”
means the consummation of the Merger and the transactions contemplated thereby.
“Closing
Date” means the date of the Closing.
“Code”
means the United States Internal Revenue Code of 1986, as amended.
“CVRs”
means the contractual contingent value rights of Holders that are granted by Purchaser to Initial Holders as additional consideration
for the Offer and the Merger pursuant to the terms of the Offer and the Merger Agreement. Unless otherwise specified herein, for purposes
of this Agreement all the CVRs shall be considered as part of and shall act as one class only. For the avoidance of doubt, Purchaser
shall only grant CVRs to the Initial Holders, and shall not grant further CVRs to any other Persons at any other time during the pendency
of this Agreement, pursuant and subject to the terms hereof.
“CVR
Payment Amount” means, for a given Holder, an amount equal to:
(a)
the CVR Proceeds, multiplied by
(b)
(i) the total number of CVRs entitled to receive such CVR Proceeds held by such Holder, divided by (ii) the total number of CVRs entitled
to receive such CVR Proceeds held by all Holders, each as reflected on the CVR Register as of the close of business on the date prior
to the date of payment (rounded down to the nearest whole cent per Holder).
“CVR
Payment Date” means (a) with respect to a Development CVR Payment, no later than 30 days following, as applicable, (i) the
receipt of Gross Proceeds by Rain, Parent or any of their respective Affiliates, pursuant to which CVR Proceeds from a Disposition are
payable to Holders hereunder, or (ii) the achievement of the Development Milestone (as defined below) pursuant to which CVR Proceeds
are payable to Holders hereunder and (b) with respect to a Cash CVR Payment, (i) with respect to a Cash CVR Payment consisting of the
Excess Cash Adjustment (if any), no later than 30 days following final determination of such Excess Cash Adjustment, and (ii) with respect
to any other Cash CVR Payment, no later than 30 days following the later of (A) the final and non-appealable resolution of any Rain Litigation
or (B) the first anniversary of the Closing Date.
“CVR
Payment Notice” has the meaning set forth in Section 2.4(c).
“CVR
Period” means the period beginning on the Closing Date and ending on (a) with respect to a Development CVR Payment, the Development
CVR Payment Expiration Date and (b) with respect to a Cash CVR Payment, the Cash CVR Payment Expiration Date.
“CVR
Proceeds” means, as applicable:
(a)
(i) if one or more Dispositions occurs prior to the Development Milestone being achieved, 80% of the Net Proceeds from such Disposition(s),
or (ii) if the Development Milestone is achieved prior to the occurrence of any Disposition, $1,000,000; provided that Parent
may, in its reasonable discretion, withhold up to 20% of the CVR Proceeds consistent with the Disposition Agreement giving rise to the
CVR Proceeds for the satisfaction of indemnity obligations under any Disposition Agreement in excess of any escrow fund established therein,
in each case to the extent not already deducted as Permitted Deductions; provided, further, that any such withheld CVR
Proceeds shall be distributed (net of any Permitted Deductions satisfied therefrom) to the Holders no later than three (3) years following
the applicable CVR Payment Date on which such CVR Proceeds would have otherwise been distributed to the Holders; provided, further,
that such withholding shall not be permitted if the applicable indemnification period under the applicable Disposition Agreement related
to such CVR Proceeds has expired by its terms when the CVR Proceeds are received (it being understood, for the avoidance of doubt, that
CVR Proceeds shall be either the amount in subsection (i) or the amount in the subsection (ii) (depending on the relative timing of a
Disposition and the Development Milestone), and shall in no event be the sum or other combination of these two amounts) (any payment
of CVR Proceeds that becomes payable in accordance with the criteria set forth in this clause (a), a “Development CVR Payment”);
(b)
(i) if the amount of Company Net Cash as of 11:59 pm ET on the Expiration Date of the Offer calculated in accordance with clause (b)(v)
of Exhibit A to the Merger Agreement (which for the avoidance of doubt, this calculation the “Final Company Net Cash”)
is greater than $49,600,000, the amount of such excess (the “Excess Cash Adjustment”); and
(c)
an amount equal to (A) $5,000,000, minus (B) all damages or losses (including special, punitive or indirect, consequential or
incidental loss or damage of any kind as may be determined by a court in a final non-appealable judgment, including but not limited to
lost profits), judgments, settlements and out-of-pocket costs and expenses (including court-ordered interest, court costs and fees and
costs of attorneys, accountants and other experts, or other expenses of litigation or other proceedings or of any claim, default or assessment)
incurred by Parent or its Affiliates (including Rain following the Merger) related to any Rain Litigation (the foregoing, collectively,
“Rain Litigation Expenses”), minus (C) if Final Company Net Cash is less than $49,600,000, the amount of such
shortfall (the “Company Net Cash Shortfall”) (any payment of CVR Proceeds that becomes payable in accordance with
the criteria set forth in this clauses (b) or (c), a “Cash CVR Payment”). For avoidance of doubt, the parties acknowledge
and agree that the calculation of Final Company Net Cash is not intended to be used to permit the introduction of different judgments,
accounting methodologies (including with respect to accruals and reserves), policies, principals, practices, procedures or classifications
for purposes of calculating Company Net Cash;
“CVR
Products” means milademetan (including any form or formulation thereof and any improvement or enhancement thereof), as well
as any combination product in which at least one other active pharmaceutical ingredient is co-formulated or packaged together with milademetan
(including any form or formulation thereof and any improvement or enhancement thereof).
“CVR
Register” has the meaning set forth in Section 2.3(b).
“Development
CVR Payment Expiration Date” means the date of the expiration of the Development Milestone Period; provided that, to the extent
a Disposition or the achievement of the Development Milestone takes place prior to the expiration of the Development Milestone Period,
the Development CVR Payment Expiration Date (in the event of a Disposition, solely as it relates to the CVR Products in such Disposition)
shall be the earliest to occur of (a) the date that is the tenth anniversary of the Closing Date, and (b) the delivery by the Rights
Agent to each Holder of all potential CVR Payment Amounts (if any) required to be paid under the terms of this Agreement and, if applicable,
the related Disposition Agreement(s). For the avoidance of doubt, no CVR Payment Amounts will be due with respect to Dispositions following
achievement of the Development Milestone.
“Development
Milestone” means the dosing of the first patient with a CVR Product in a clinical study conducted by Rain, Parent or any of
their respective Affiliates during the Development Milestone Period.
“Development
Milestone Period” means the period beginning on the Effective Time and ending on the fifth anniversary of the Closing Date.
“Disposition”
means the sale, transfer or other disposition by Parent or any of its Affiliates, including Rain (after the Merger), of all or any part
of any CVR Products to any Person who is not an Affiliate of Parent, whether by assignment, license, or otherwise, in each case during
the Disposition Period but in all cases excluding licenses or transfers of materials to consultants, subcontractors, vendors, other service
providers, or academic collaborators for the purpose of enabling the performance of services for Parent or any of its Affiliates. For
avoidance of doubt, a Change of Control (substituting “Parent” for “Purchaser” in the definition of Change of
Control) will not in itself be a Disposition.
“Disposition
Agreement” means a definitive agreement, contract or other document providing for a Disposition that is entered into by, on
the one hand, Parent or any of its Affiliates, including Rain (after the Merger), and, on the other hand, any Person who is not Parent
or an Affiliate of Parent and which is entered into prior to the end of the Disposition Period, but in all cases excluding licenses or
transfers of materials to consultants, subcontractors, vendors, other service providers, or academic collaborators for the purpose of
enabling the performance of services for Parent or any of its Affiliates.
“Disposition
Period” means the period beginning on the Effective Time and ending on the second anniversary of the Closing Date.
“DTC”
means The Depository Trust Company or any successor thereto.
“Equity
Award CVR” means a CVR received by a Holder in respect of Rain RSUs.
“Governmental
Entity” means any United States or non-United States federal, national, supranational, state, provincial, local or similar
government, governmental, regulatory or administrative authority, branch, agency or commission or any court, tribunal, or arbitral or
judicial body (including any grand jury).
“Gross
Proceeds” means, without duplication, the sum of all cash consideration and the value of any and all consideration of any kind
that is paid to, and actually received by, Parent or any of its Affiliates, or is received by, Parent or any of its Affiliates during
the CVR Period in respect of a Disposition, solely as such consideration relates to a CVR Product. The value of any securities (whether
debt or equity) or other non-cash property constituting Gross Proceeds shall be determined as follows: (a) the value of securities for
which there is an established public market shall be equal to the volume weighted average of their closing market prices for the five
trading days ending the day prior to the date of payment to, or receipt by, Parent or its relevant Affiliate, and (b) the value of securities
that have no established public market and the value of consideration that consists of other non-cash property, shall be the fair market
value thereof as of the date of payment to, or receipt by, Parent or its relevant Affiliate; provided, that Parent may elect,
upon prompt notice to the Representative after Parent’s receipt of consideration, to have any securities or other non-cash property
specified in the foregoing clause (b) be deemed as Gross Proceeds only upon the earlier of (i) the receipt by Parent or any of its Affiliates
of cash in respect of the sale or other liquidation by Parent or its Affiliates of such securities or other non-cash property, and the
value of such cash shall be Gross Proceeds upon receipt by Parent or any of its Affiliates, or (ii) the second anniversary of receipt
of such securities or other non-cash property, and the value of such consideration shall be Gross Proceeds as of such date with a value
equal to the greater of (A) the fair market value of such securities or other non-cash property as of the date originally received by
Parent or its relevant Affiliate or (B) the fair market value of such securities or other non-cash property as of such date as reasonably
determined by Parent, and all other consideration, if any, paid to or received by Parent or any of its Affiliates will be deemed Gross
Proceeds upon receipt by Parent or its relevant Affiliate. In the event that any such Disposition includes the sale of CVR Products or
other products, businesses or assets other than solely milademetan (“Other Products”), Parent shall in good faith assign
an allocation of value to milademetan and the Other Products under such sale, and only the amount allocated to milademetan shall be included
in the calculation of Gross Proceeds.
“Holder”
means, at the relevant time, a Person in whose name a CVR is registered in the CVR Register at the applicable time.
“Intended
Tax Treatment” has the meaning set forth in Section 2.5(a).
“Law”
means any foreign or U.S. federal, state or local law (including common law), treaty, statute, code, order, ordinance, approval, authorization,
certificate, registration, exemption, consent, license, order, permit and other similar authorizations, rule, regulation, or other requirement
issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Entity.
“Net
Proceeds” means, for a Disposition, the Gross Proceeds minus Permitted Deductions, as calculated in a manner consistent with
generally accepted accounting principles in the United States set forth in the opinions and pronouncements of the Accounting Principles
Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards
Board, consistently applied. For clarity, (i) if Permitted Deductions exceed Gross Proceeds as it relates to a certain Disposition, any
excess Permitted Deductions shall be applied against Gross Proceeds in a subsequent Disposition, and (ii) if any of the Gross Proceeds
or Permitted Deduction are not in U.S. dollars, currency conversion to U.S. dollars shall be made by using the exchange rate prevailing
at the JP Morgan Chase Bank or its successor entity on the date of receipt of such Gross Proceeds or date of payment of relevant Permitted
Deductions, as applicable.
“Officer’s
Certificate” means a certificate signed by an authorized officer of Parent, in his or her capacity as such an officer, and
delivered to the Rights Agent and the Representative.
“Permitted
CVR Transfer” means: a transfer of CVRs (a) upon death of a Holder by will or intestacy; (b) pursuant to a court order; (c)
by operation of law (including by consolidation or merger) or without consideration in connection with the dissolution, liquidation or
termination of any corporation, limited liability company, partnership or other entity; (d) in the case of CVRs held in book-entry or
other similar nominee form, from a nominee to a beneficial owner and, if applicable, through an intermediary, to the extent allowable
by DTC; or (e) as provided in Section 2.7.
“Permitted
Deductions” means the sum of, without duplication, the following costs or expenses:
(a) any
applicable Taxes (including any applicable value added or sales Taxes) imposed on Gross Proceeds and payable by Parent or any of its
Affiliates and any current income or other Taxes payable by Parent or any of its Affiliates that would not have been incurred by Parent
or its Affiliates but for the Gross Proceeds having been received or accrued by Parent or its Affiliates; provided that for purposes
of calculating income Taxes payable by Parent or its Affiliates in respect of the Gross Proceeds, any such income Taxes shall be computed
after taking into account any net operating loss carryforwards or other Tax attributes (including Tax credits) of Rain or its Affiliates
as of the Closing Date prior to the Effective Time that are available to offset such gain after taking into account any limits of the
usability of such attributes applicable as of the Closing Date prior to the Effective Time (or arising as a result of the Closing), including
under Section 382 of the Code as reasonably determined by a nationally recognized tax advisor; provided further that any such
net operating loss carryforwards or other Tax attributes of Rain or its Affiliates will first be applied to the computation of income
Taxes imposed on Gross Proceeds or that would not have been incurred but for the Gross Proceeds having been received or accrued by Parent
or its Affiliate;
(b) any
reasonable and documented out-of-pocket costs and expenses incurred by Parent or any of its Affiliates in connection with the applicable
CVR Product(s) in respect of a Disposition, including technology transfer costs, contractual expenses or any costs in respect of head
licenses for sublicensed technology and the development or prosecution, maintenance or enforcement by Parent or any of its Subsidiaries
of intellectual property rights but excluding any costs related to a breach of this Agreement, any expenses included in the calculation
of Final Company Net Cash to the extent paid prior to the Closing or identified on the Final Company Net Cash Schedule delivered on the
Expiration Date to be paid following the Closing and the negotiation, execution and performance of any of the foregoing;
(c) (i)
any reasonable and documented out-of-pocket costs and expenses incurred by Parent or any of its Affiliates in connection with Disposition
business development related efforts with respect to the relevant CVR Product(s) during the Disposition Period, and (ii) maintenance
costs related to the CVRs or the CVR Products (including fees and expenses related to the Rights Agent and the Representative); and
(d) any
reasonable and documented out-of-pocket costs incurred or accrued by Parent or any of its Affiliates in connection with Parent’s
efforts to negotiate or enter into any Disposition Agreement or consummate a Disposition of any applicable CVR Product(s), including
any Representative fee, Rights Agent fee, brokerage fee, finder’s fee, opinion fee, success fee, transaction fee, service fee or
other fee, commission or expense owed to any broker, finder, investment bank, auditor, accountant, counsel, advisor or other third party
in relation thereto (but excluding any costs or expenses previously deducted from Gross Proceeds);
In
addition, Permitted Deductions shall include any Gross Proceeds that (x) constitute (i) compensation to Parent or Purchaser for the provision
of goods and/or services by Parent or Purchaser to the counterparty in such Disposition (including research and development funding provided
by such counterparty), (ii) reimbursement of patent expenses, or (iii) a bona fide loan and (y) which amounts were consented to in writing
by the Representative (such consent not to be unreasonably withheld, conditioned or delayed).
“Person”
means any individual, firm, corporation, limited liability company, partnership, trust or other entity, and shall include any successor
(by merger or otherwise) thereof or thereto.
“Rain
Common Stock” means the shares of common stock, par value $0.001 per share, of Rain.
“Rain
Litigation” means any Legal Proceeding against or involving Rain and its directors and/or officers that is either (a) included
in the definition of Litigation Matters set forth in the Merger Agreement or (b) otherwise existing as of the date hereof or arising
following the date hereof and prior to the first anniversary of the Closing Date.
“Rain
RSU” means each restricted stock unit settleable in Rain Common Stock granted under the Company Stock Plans outstanding as
of immediately prior to the Effective Time.
“Rights
Agent” means the Rights Agent named in the first paragraph of this Agreement, until a successor Rights Agent will have become
such pursuant to the applicable provisions of this Agreement, and thereafter “Rights Agent” will mean such successor
Rights Agent.
“Tax”
or “Taxes” means any and all federal, state, local, or non-U.S. income, gross receipts, license, payroll, employment,
excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding,
social security (or similar, including FICA), unemployment, disability, real property, personal property, sales, use, transfer, registration,
value-added, alternative or add-on minimum or other tax of any kind or any charge of any kind in the nature of (or similar to) taxes
whatsoever imposed by a Governmental Entity, including any interest, penalty or addition thereto.
Section
1.2 Rules of Construction.
(a) As
used in this Agreement, any noun or pronoun will be deemed to include the plural as well as the singular and to cover all genders.
(b) This
Agreement will be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting
or causing any instrument to be drafted. The parties hereto have participated jointly in the negotiation and drafting of this Agreement
and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by
the parties hereto and no presumption of burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of
this Agreement.
(c) As
used in this Agreement, the words “include,” “includes,” or “including” will be deemed to be followed
by the words “without limitation.” The words “hereof,” “herein,” “hereby,” “hereto,”
and “hereunder” and words of similar import when used in this Agreement will refer to this Agreement as a whole and not to
any particular provision of this Agreement. The word “or” will not be exclusive.
(d) When
reference is made in this Agreement to an Article or Section, such reference will refer to Articles and Sections of this Agreement, as
the case may be, unless otherwise indicated.
(e) The
headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall
not be referred to in connection with the construction or interpretation of this Agreement.
(f) All
references to $ are to United States dollars.
ARTICLE
II
CONTINGENT VALUE RIGHTS
Section
2.1 CVRs. The CVRs represent the contractual rights of Holders to receive contingent cash payment of the CVR Proceeds from
Purchaser pursuant to this Agreement.
Section
2.2 Nontransferable. The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred
or disposed of, in whole or in part, other than through a Permitted CVR Transfer. Any attempted sale, assignment, transfer, pledge, encumbrance
or disposition of CVRs, in whole or in part, in violation of this Section 2.2 shall be void ab initio and of no effect.
Section
2.3 No Certificate; Registration; Registration of Transfer; Change of Address.
(a) The
CVRs will be issued and distributed by Purchaser to each Holder in book-entry form only and will not be evidenced by a certificate or
other instrument.
(b) The
Rights Agent will keep a register (the “CVR Register”) for the purpose of (i) identifying the Holders of CVRs and
(ii) registering CVRs and Permitted CVR Transfers thereof. The CVR Register will initially show one position for Cede & Co. representing
all the Rain Common Stock held by DTC on behalf of the street holders of the Rain Common Stock held by such Holders as of immediately
prior to the Effective Time. The Rights Agent will have no responsibility whatsoever directly to the street name holders with respect
to transfers of CVRs unless and until such CVRs are transferred into the name of such street name holders in accordance with Section
2.2. With respect to any payments to be made under Section 2.4 below, the Rights Agent will accomplish the payment to
any former street name holders of Rain Common Stock by sending one lump payment to DTC. The Rights Agent will have no responsibilities
whatsoever with regard to the distribution of payments by DTC to such street name holders. Upon request of a Holder or the Representative,
the Rights Agent will make available to such Holder or the Representative, as applicable, a list of the other Holders, the number of
CVRs held by each Holder, the contact information maintained by the Rights Agent with respect to each Holder and such other information
relating to this Agreement as may be reasonably requested by the Representative.
(c) Subject
to the restrictions on transferability set forth in Section 2.2, every request made to transfer a CVR must be in writing
and accompanied by a written instrument of transfer, in form reasonably satisfactory to the Rights Agent pursuant to its guidelines,
duly executed by the Holder thereof, the Holder’s attorney duly authorized in writing, the Holder’s personal representative
duly authorized in writing, or the Holder’s survivor (with written documentation evidencing such Person’s status as the Holder’s
survivor), and setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the
Rights Agent will, subject to its reasonable determination that the transfer instrument is in proper form and the transfer otherwise
complies with the other terms and conditions of this Agreement (including the provisions of Section 2.2), register the transfer
of the CVRs in the CVR Register. As a condition of such transfer, Parent and Rights Agent may require a transferring Holder or its transferee
to pay to the applicable Governmental Entity any transfer, stamp, documentary, registration, or other similar Tax or governmental charge
that is imposed in connection with any such registration of transfer. The Rights Agent shall have no duty or obligation to take any action
under any section of this Agreement that requires the payment by a Holder of a CVR of such applicable Taxes or charges unless and until
the Rights Agent is reasonably satisfied that all such Taxes or charges have been paid or that such Taxes or charges are not applicable.
All duly transferred CVRs registered in the CVR Register will be the valid obligations of Purchaser and will entitle the transferee to
the same benefits and rights under this Agreement as those held immediately prior to the transfer by the transferor. No transfer of a
CVR will be valid until registered in the CVR Register in accordance with this Agreement.
(d) A
Holder may make a written request to the Rights Agent to change such Holder’s address of record in the CVR Register. The written
request must be duly executed by the Holder. Upon receipt of such written notice, the Rights Agent will promptly record the change of
address in the CVR Register.
Section
2.4 Payment Procedures: Notices.
(a) With
respect to Development CVR Payments, if (i) a Disposition Agreement is entered into during the Disposition Period prior to achievement
of the Development Milestone, or (ii) the Development Milestone is achieved during the Development Milestone Period prior to the occurrence
of a Disposition, then in each case Parent shall promptly deliver to the Rights Agent (with a copy to the Representative) written notice
indicating: (A) a Disposition Agreement has been entered into and a copy of the Disposition Agreement and any ancillary agreements thereto,
or (B) the Development Milestone has been achieved, as applicable.
(b) With
respect to Cash CVR Payments, if CVR Proceeds are payable to Holders in accordance with clause (b) of the definition of “CVR Proceeds”
as of 11:59 pm ET on the Expiration Date of the Offer, Parent shall promptly deliver to the Rights Agent (with a copy to the Representative)
written notice indicating the amount of such CVR Proceeds. Upon the final and non-appealable resolution of any Rain Litigation, Parent
shall promptly deliver to the Rights Agent (with a copy to the Representative) written notice of such resolution.
(c) On
or prior to each CVR Payment Date, Parent shall deliver to the Rights Agent (with a copy to the Representative) (i) written notice indicating
that (A) the Holders are entitled to receive one or more payments of CVR Proceeds, (B) the source and trigger event for such payment
of CVR Proceeds, and (C) if applicable, with respect to a Development CVR Payment, a detailed calculation of Gross Proceeds, Net Proceeds
and any Permitted Deductions used to calculate such CVR Proceeds with reasonable supporting detail for such Permitted Deductions and
with respect to a Cash CVR Payment, a detailed calculation of Rain Litigation Expenses and the Company Net Cash Shortfall, if any, used
to calculate such CVR Proceeds with reasonable supporting detail (each such notice, a “CVR Payment Notice”) and (ii)
any letter of instruction reasonably required by the Rights Agent. On or prior to any CVR Payment Date, Parent shall deliver to the Rights
Agent the CVR Payment Amounts required by Section 4.2. All payments by Parent hereunder shall be made in U.S. dollars. For
the avoidance of doubt, Parent shall have no further liability in respect of the relevant CVR Payment Amount upon delivery of such CVR
Payment Amount in accordance with this Section 2.4(c) and the satisfaction of each of Parent’s obligations set forth
in this Section 2.4(c).
(d) The
Rights Agent will promptly, and in any event within 10 Business Days after receipt of the CVR Payment Notice as well as any letter of
instruction reasonably required by the Rights Agent, send each Holder at its registered address a copy of the CVR Payment Notice and,
following the applicable CVR Payment Date, promptly pay the CVR Payment Amount to each of the Holders entitled to receive such CVR Payment
Amount by check mailed to the address of each Holder as reflected in the CVR Register as of the close of business on the CVR Payment
Date.
(e) Any
portion of the CVR Payment Amount that remains undistributed to a Holder six months after the date of the delivery of the applicable
CVR Payment Date will be delivered by the Rights Agent to Parent or Purchaser, upon demand, and any Holder will thereafter look only
to Parent and Purchaser for payment of the CVR Payment Amount, without interest, but such Holder will have no greater rights against
Parent and Purchaser than those accorded to general unsecured creditors of Parent and Purchaser under applicable Law.
(f) None
of Parent, any of its Affiliates (including Purchaser) or the Rights Agent will be liable to any Person in respect of the CVR Payment
Amount delivered to a public official pursuant to any applicable abandoned property, escheat or similar Law. If, despite Parent’s,
any of its Affiliates’ and/or the Rights Agent’s commercially reasonable efforts to deliver the CVR Payment Amount to the
applicable Holder, the CVR Payment Amount has not been paid within two years after the applicable CVR Payment Date (or immediately prior
to an earlier date on which the CVR Payment Amount would otherwise escheat to or become the property of any Governmental Entity), the
CVR Payment Amount will, to the extent permitted by applicable Law, become the property of Parent or Purchaser, free and clear of all
claims or interest of any Person previously entitled thereto. In addition to and not in limitation of any other indemnity obligation
herein, Parent and Purchaser agree to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense
the Rights Agent may incur or be subject to in connection with transferring such property to Parent or Purchaser.
Section
2.5 Tax Matters.
(a) Except
to the extent any portion of the CVR Payment Amount is required to be treated as imputed interest pursuant to applicable Law, the parties
intend that, for all U.S. federal and applicable state and local income Tax purposes, (i) the CVRs received in respect of Shares (which
for avoidance of doubt does not include the Equity Award CVRs) will be treated as additional consideration paid with respect to such
Shares in connection with the Offer or the Merger, as the case may be, (ii) any CVR Payment Amount received in respect of such CVRs will
be treated as an amount realized on the disposition or partial disposition of the applicable CVRs, and (iii) any CVR Payment Amount paid
in respect of any Equity Award CVR will be treated as wages in the year in which the CVR Payment Amount is made (and not upon the receipt
of such CVR) (clauses (i) through (iii), collectively, (the “Intended Tax Treatment”)). Unless otherwise required
(A) by a “determination” within the meaning of Section 1313(a) of the Code (or a similar determination under applicable state
or local Law) or (B) by a nationally recognized accounting firm, the parties to this Agreement shall file all U.S. federal, state and
local Tax Returns in a manner consistent with the Intended Tax Treatment, and no party shall take or cause another to take, a position
or action inconsistent with such treatment, or fail to take, or knowingly fail to cause another to take, a position or action, where
the failure to take such position or action is inconsistent with such treatment. For the avoidance of doubt, nothing herein is intended
to impose on the Representative any obligation to prepare or file any Tax Returns.
(b) In
addition to any Permitted Deductions, Parent and its Affiliates (including Purchaser) and the Rights Agent shall be entitled to deduct
and withhold, or cause to be deducted or withheld, from each CVR Payment Amount or any other amounts otherwise payable pursuant to this
Agreement such amounts as may be required to be deducted and withheld therefrom under applicable Law. With respect to Holders who received
Equity Award CVRs, any such withholding may be made, or caused to be made, by Parent through the payroll system or any successor payroll
system of Parent or any of its Affiliates, including Rain following the Merger. Prior to making (or causing to be made) any such Tax
deduction or withholding, Parent shall instruct the Rights Agent to provide the opportunity for the Holders to provide duly executed
Internal Revenue Service (IRS) Forms W-9 or W-8, as applicable, or any other reasonably appropriate forms or information from Holders
in order to avoid or reduce withholding. The Rights Agent shall promptly and timely remit, or cause to be remitted, any amounts withheld
in respect of Taxes to the appropriate Governmental Entity. To the extent any amounts are so deducted and withheld, such amounts shall
be treated for all purposes of this Agreement as having been paid to the Person in respect of whom such deduction and withholding was
made.
(c) It
is intended that each payment provided under this Agreement with respect to an Equity Award CVR (the “Payments”) is
a separate “payment” for purposes Section 1.409A-2(b)(2)(i) of the U.S. Treasury Regulations. For the avoidance of doubt,
it is intended that the Payments satisfy, to the greatest extent possible, the exemption from the application of Section 409A of the
Code and the Treasury Regulations and other guidance issued thereunder and any state law of similar effect (collectively “Section
409A”) provided under Treasury Regulations Section 1.409A-1(b)(4) and, to the extent not so exempt, that the Payments comply,
and this Agreement be interpreted to the greatest extent possible, as consistent with Treasury Regulations Section 1.409A-3(i)(5)(iv)(A)
— that is, as “transaction-based compensation.” To the extent this Agreement (and any definitions hereunder), or any
payments hereunder, are not exempt, they shall be construed in a manner that complies with Section 409A, including by reason of satisfying
the “transaction-based compensation” provisions thereunder, including the five-year post-Closing payment limitation therein,
and shall incorporate by reference all required definitions and payment terms. Notwithstanding the foregoing, none of the parties hereto
nor any of their employees, directors or representatives make any representation or warranty and will have no liability to a Holder or
transferee or other Person if any payments under any provisions of this Agreement are determined to constitute deferred compensation
under Section 409A of the Code (or any similar U.S. state Tax Law) that are subject to certain additional federal, state or other Taxes.
Parent may provide each recipient of an Equity Award CVR with a notice or award agreement setting forth the terms and condition of the
Holder’s entitlement to payments under such Equity Award CVR in accordance with the terms of this Agreement.
Section
2.6 No Voting, Dividends or Interest; No Equity or Ownership Interest in Parent or any of its Affiliates.
(a) The
CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable on the CVRs to any Holder.
(b) The
CVRs will not represent any equity or ownership interest in Parent, any constituent corporation party to the Merger or any of their respective
Affiliates. It is hereby acknowledged and agreed that a CVR shall not constitute a security of Parent.
(c) Nothing
contained in this Agreement shall be construed as conferring upon any Holder, by virtue of the CVRs, any rights or obligations of any
kind or nature whatsoever as a stockholder or member of Parent or any of its Subsidiaries either at law or in equity. The rights of any
Holder and the obligations of Parent and its Affiliates and their respective officers, directors and controlling Persons are contract
rights limited to those expressly set forth in this Agreement.
(d) Each
Holder, by virtue of the approval of the Merger and this Agreement by the Initial Holders and/or the receipt of any consideration in
connection with the Merger, and without any further action of any of the Holders or Rain, acknowledges and agrees to the appointment
and authority of the Representative to act as the exclusive representative, agent and attorney-in-fact of such Holder and all Holders
as set forth in this Agreement, which shall include the power and authority of the Representative to take or refrain from taking the
actions specified herein and any other actions relating to the subject matter of this Agreement as determined by the Representative.
Notwithstanding the foregoing or anything else herein, the Representative shall have no obligation to act on behalf of the Holders except
as expressly provided herein and in the Representative Engagement Agreement, and for purposes of clarity, there are no obligations of
the Representative in any ancillary agreement, schedule, exhibit or disclosure schedule. The powers, immunities and rights to indemnification
granted to the Representative Group hereunder: (i) are coupled with an interest and shall be irrevocable and survive the death, incompetence,
bankruptcy or liquidation of any Holder and shall be binding on any successor thereto, and (ii) shall survive the delivery of an assignment
by any Holder of the whole or any fraction of his, her or its interest in the CVRs or other interest herein.
(e) Neither
Parent nor any of its Affiliates, nor their respective boards of directors and officers will be deemed to have any fiduciary or similar
duties or any implied duties to any Holder by virtue of this Agreement. All actions taken by the Representative under this Agreement
or the Representative Engagement Agreement shall be binding upon each Holder and such Holder’s successors as if expressly confirmed
and ratified in writing by such Holder, and all defenses which may be available to any Holder to contest, negate or disaffirm the action
of the Representative taken in good faith under this Agreement or the Representative Engagement Agreement are waived.
(f) It
is hereby acknowledged and agreed that the CVRs and the possibility of any payment hereunder with respect thereto are highly speculative
and subject to numerous factors outside of Parent’s or Rain’s control, and there is no assurance that Holders will receive
any payments under this Agreement or in connection with the CVRs. The parties acknowledge that it is possible that (i) no Disposition
will occur during the Disposition Period, (ii) the Development Milestone will not be achieved during the Development Milestone Period,
(iii) there will not be any Gross Proceeds that may be the subject of a CVR Payment Amount, and (iv) there will not be any CVR Proceeds
with respect to the Cash CVR Payments. It is further acknowledged and agreed that the parties hereto intend solely that the express provisions
of this Agreement will govern their contractual relationship with respect to the CVRs. It is acknowledged and agreed that Section
2.6(e) and this Section 2.6(f) are essential and material terms of this Agreement.
Section
2.7 Ability to Renounce or Abandon CVR. Notwithstanding anything to the contrary contained herein, any Holder or Holder’s
successor or assign pursuant to a Permitted CVR Transfer may, at any time, at such Holder’s option, agree to renounce, in whole
or in part, its rights under this Agreement and abandon all of such Holder’s remaining rights in a CVR by transferring such CVR
to Purchaser or Parent without consideration therefor, effected by written notice to the Rights Agent, the Representative and Parent,
which renouncement and abandonment notice, if given, shall be irrevocable and effective upon the sending of such notice. Nothing in this
Agreement shall prohibit Parent or any of its Affiliates (including Purchaser) from offering to acquire or acquiring any CVRs for consideration
from the Holders, in private transactions or otherwise, in its sole discretion. Any CVRs acquired by Parent or any of its Affiliates
(including Purchaser) shall be automatically deemed extinguished and no longer outstanding for purposes of the definition of Acting Holders
and ARTICLE VI and Section 6.3 hereunder.
ARTICLE
III
THE RIGHTS AGENT
Section
3.1 Certain Duties and Responsibilities. The Rights Agent shall not have any liability for any actions taken or failed to be
taken by it in connection with this Agreement, except to the extent of its bad faith, gross negligence, fraud or willful misconduct.
Section
3.2 Certain Rights of Rights Agent. The Rights Agent undertakes to perform such duties and only such duties as are specifically
set forth in this Agreement, and no implied covenants or obligations will be read into this Agreement against the Rights Agent. In addition:
(a) the
Rights Agent may rely on and will be protected and held harmless by Parent in acting or refraining from acting upon any resolution, certificate,
statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it in good
faith to be genuine and to have been signed or presented by the proper party or parties;
(b) whenever
the Rights Agent deems it desirable that a matter be proved or established prior to taking or not taking any action hereunder, the Rights
Agent may (i) rely upon an Officer’s Certificate, which certificate shall be full authorization and protection to the Rights Agent,
and the Rights Agent shall, in the absence of bad faith, gross negligence, fraud or willful misconduct on its part, and (ii) incur no
liability and be held harmless by Parent for or in respect of any action taken or failed to be taken by it under the provisions of this
Agreement in reliance upon such Officer’s Certificate;
(c) the
Rights Agent may engage and consult with counsel of its selection and the advice of such counsel or any opinion of counsel shall, in
the absence of bad faith, gross negligence, fraud or willful misconduct, be full and complete authorization and protection to the Rights
Agent, and the Rights Agent shall be held harmless by Parent in respect of any action taken or failed to be taken by it hereunder in
good faith and in reliance thereon;
(d) the
permissive rights of the Rights Agent to do things enumerated in this Agreement will not be construed as a duty;
(e) the
Rights Agent will not be required to give any note or surety in respect of the execution of such powers or otherwise in respect of the
CVR Proceeds;
(f) the
Rights Agent shall not be liable for or by reason of, and shall be held harmless by Parent with respect to any of the statements of fact
or recitals contained in this Agreement or be required to verify the same (in the absence of its bad faith, gross negligence, fraud or
willful misconduct), but all such statements and recitals are and shall be deemed to have been made by Parent only;
(g) the
Rights Agent shall have no liability (in the absence of its bad faith, gross negligence, fraud or willful misconduct) and shall be held
harmless by Parent in respect of the validity of this Agreement or the execution and delivery hereof (except the due execution and delivery
hereof by the Rights Agent and the enforceability of this Agreement against the Rights Agent assuming the due execution and delivery
hereof by Parent), nor shall it be responsible for any breach by Parent of any covenant or condition contained in this Agreement;
(h) Parent
agrees to indemnify the Rights Agent for, and hold the Rights Agent harmless against, any loss, liability, damage, judgment, fine, penalty,
cost or expense (each, a “Loss”) incurred or suffered by the Rights Agent, including the reasonable, documented and
necessary out-of-pocket costs and expenses of counsel, as a result of any claims, charges, demands, actions or suits brought by any Person
other than Parent or its Affiliates arising out of or in connection with the proper execution, acceptance, administration, exercise and
performance by the Rights Agent of its duties under this Agreement, unless such Loss has been determined by a court of competent jurisdiction
to be a result of Rights Agent’s gross negligence, fraud, bad faith or willful misconduct; provided that this Section
3.2(h) shall not apply with respect to income, receipt, franchise or similar Taxes;
(i) Parent
agrees (i) to pay the fees and expenses of the Rights Agent in connection with this Agreement as agreed upon in writing by the Rights
Agent and Parent on or prior to the date hereof and (ii) to reimburse the Rights Agent for all reasonable, documented and necessary out-of-pocket
expenses paid or incurred by the Rights Agent after the Effective Time in connection with the administration by the Rights Agent of its
duties hereunder, including all stamp and transfer Taxes (and excluding for the avoidance of doubt any income, receipt, franchise or
similar Taxes) and governmental charges;
(j) to
the extent the Parent is not also a party to any action, proceeding, suit or claim against the Rights Agent concerning this Agreement
or the performance by the Rights Agent of its duties hereunder, the Rights Agent shall notify the Parent in accordance with Section
6.1 of the assertion of such action, proceeding, suit or claim against the Rights Agent as promptly as practicable after the Rights
Agent has actual notice of such assertion of an action, proceeding, suit or claim or have been served with the summons or other first
legal process giving information as to the nature and basis of the action, proceeding, suit or claim; provided that the failure
to provide such notice promptly shall not affect the rights of the Rights Agent hereunder, except to the extent a court of competent
jurisdiction determines that such failure actually prejudiced Parent. Parent shall be entitled to participate at its own expense in the
defense of any such action, proceeding, suit or claim. The Rights Agent agrees not to settle any litigation in connection with any action,
proceeding, suit or claim with respect to which it may seek indemnification from the Parent without the prior written consent of Parent,
which shall not be unreasonably withheld, conditioned or delayed; and
(k) no
provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability
in the performance of any of its duties hereunder or in the exercise of its rights if there shall be reasonable grounds for believing
that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it.
Section
3.3 Resignation and Removal; Appointment of Successor.
(a) The
Rights Agent may resign at any time by giving written notice thereof to Parent (with a copy to the Representative) specifying a date
when such resignation will take effect, which notice will be sent at least 30 days prior to the date so specified and such resignation
will be effective on the earlier of: (i) the date so specified, and (ii) a successor Rights Agent has been appointed and accepted such
appointment in accordance with Section 3.5. The Representative shall have the right to remove Rights Agent at any time by
specifying a date when such removal will take effect but no such removal will become effective until a successor Rights Agent has been
appointed. Notice of such removal will be given by the Representative to Rights Agent, which notice will be sent at least 60 days prior
to the date so specified.
(b) If
the Rights Agent provides notice of its intent to resign, is removed pursuant to Section 3.3(a) or becomes incapable of acting,
Parent and the Representative, acting in concert, will, as soon as is reasonably possible, appoint a qualified successor Rights Agent
who, unless otherwise consented to in writing by the Acting Holders, shall be a stock transfer agent of national reputation or the corporate
trust department of a commercial bank. The successor Rights Agent so appointed will, forthwith upon its acceptance of such appointment
in accordance with Section 3.4, become the successor Rights Agent. Notwithstanding the foregoing, if Parent shall fail to
make such appointment within a period of 30 days after giving notice of such removal or after it has been notified in writing of such
resignation or incapacity by the resigning or incapacitated Rights Agent, then the Acting Holders may apply to any court of competent
jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed shall, forthwith upon its acceptance
of such appointment in accordance with Section 3.4, become the successor Rights Agent.
(c) Parent
will give notice of each resignation and each removal of a Rights Agent and each appointment of a successor Rights Agent by mailing written
notice of such event by first-class mail to the Holders as their names and addresses appear in the CVR Register. Each notice will include
the name and address of the successor Rights Agent. If Parent fails to send such notice within 10 Business Days after acceptance of appointment
by a successor Rights Agent in accordance with Section 3.4, the successor Rights Agent will cause the notice to be mailed
at the expense of Parent. Failure to give any notice provided for in this Section 3.3, however, shall not affect the legality
or validity of the resignation or removal of the Rights Agent or the appointment of the successor Rights Agent, as the case may be.
Section
3.4 Transition Support. The Rights Agent will cooperate with Parent, the Representative and any successor Rights Agent as reasonably
requested in connection with the transition of the duties and responsibilities of the Rights Agent to the successor Rights Agent, including
the transfer of all relevant data, including transferring the CVR Register to the successor Rights Agent.
Section
3.5 Acceptance of Appointment by Successor. Every successor Rights Agent appointed pursuant to Section 3.3(b) hereunder
will execute, acknowledge and deliver to Parent and to the retiring Rights Agent an instrument accepting such appointment and a counterpart
of this Agreement, and thereupon such successor Rights Agent, without any further act, deed or conveyance, will become vested with all
the rights, powers, trusts and duties of the retiring Rights Agent. On request of Parent or the successor Rights Agent, the retiring
Rights Agent will execute and deliver an instrument transferring to the successor Rights Agent all the rights, powers and trusts of the
retiring Rights Agent.
ARTICLE
IV
COVENANTS
Section
4.1 List of Holders. Parent will furnish or cause to be furnished to the Rights Agent (with a copy to the Representative) in
such form as Parent receives from Rain’s transfer agent (or other agent performing similar services for Parent with respect to
the stockholders of Parent), the names and addresses of the Holders of such securities within 30 days of the Closing Date.
Section
4.2 Payment of CVR Payment Amounts. Purchaser shall, promptly following receipt of Gross Proceeds with respect to a Disposition
or the achievement of the Development Milestone, determination of Final Company Net Cash or the final and non-appealable resolution of
any Rain Litigation, in each case in respect of which CVR Proceeds are payable to Holders hereunder, deposit with the Rights Agent, for
payment to the Holders in accordance with Section 2.4, the aggregate amount necessary to pay the CVR Payment Amount to each
Holder.
Section
4.3 Discretion and Decision-Making Authority.
(a) Neither
Parent nor any of its Affiliates (including Purchaser) may enter into a Disposition Agreement without providing 10 days prior written
notice to the Representative.
(b) Parent
shall reasonably comply with any maintenance obligations relating to the intellectual property pertaining to any CVR Product that are
required by any term set forth in any Disposition Agreement, to the extent such intellectual property relates to the CVR Products and
is contemplated by such Disposition Agreement.
Section
4.4 Audit Right. Upon the prior written request by the Representative, Parent shall meet at reasonable times during normal
business hours with the Representative to discuss the content of any CVR Payment Notice. Parent agrees to maintain, for at least one
year after the last possible payment of CVR Proceeds, all books and records relevant to the calculation of a CVR Payment Amount and,
if applicable, the amount of Gross Proceeds, Net Proceeds and Permitted Deductions related thereto. Subject to reasonable advance written
notice from the Representative but no more frequently than once per year, and prior execution and delivery by an independent accounting
firm of national reputation chosen by the Representative and reasonably acceptable to Parent (the “Accountant”) of
a reasonable and customary confidentiality/nonuse agreement, Parent shall permit the Representative and the Accountant, acting as agent
of the Representative (on behalf of the Holders), to have access during normal business hours to the books and records of Parent as may
be reasonably necessary to audit the calculation of such CVR Payment Amount or the calculation of the amount of Gross Proceeds, Net Proceeds
and Permitted Deductions for a period covering not more than the date commencing with the first CVR Period in which Parent or its Affiliates
receives Gross Proceeds and ending on the Development CVR Payment Expiration Date. No accounting period of Parent shall be subject to
audit more than one time unless after an accounting period has been audited by the Accountant, Parent restates its financial results
for such accounting period, in which event the Accountant may conduct a second audit of such accounting period in accordance with this
Section 4.4. The Accountant shall disclose to the Rights Agent only whether the reports are correct or not and the specific details
concerning any discrepancies. No other information shall be shared with the Rights Agent. Adjustments (including
remittances of underpayments or overpayments disclosed by such audit) shall be made by Parent to reflect the results of such audit, and
any applicable underpayment reflected in an audit report delivered to Parent shall be paid promptly by Parent to the Rights Agent for
further distribution to the Holders. Whenever such an adjustment is made, Parent shall promptly prepare a certificate setting forth such
adjustment, and a brief, reasonably detailed statement of the facts, computation and methodology accounting for such adjustment to the
extent not already reflected in the audit report and promptly file with the Rights Agent (with a copy provided to the Representative)
a copy of such report and promptly deliver to the Rights Agent (with a copy provided to the Representative) a revised CVR Payment Notice
for the relevant CVR Period. The Rights Agent shall be fully protected in relying on any such report and on any adjustment or statement
therein contained and shall have no duty or liability with respect to, and shall not be deemed to have knowledge of any such adjustment
or any such event unless and until it shall have received such report. The Representative (on behalf of the Holders) shall bear the full
cost and expense of such audit unless such audit discloses an underpayment by Parent of ten percent (10%) or more of the CVR Payment
Amount due under this Agreement, in which case Parent shall bear the actual cost and expense of such audit up to an aggregate amount
of $100,000. The Rights Agent shall be entitled to rely on any audit report delivered by the Accountant pursuant to this Section 4.4.
Section
4.5 Assignments. Parent shall not, in whole or in part, assign any of its obligations under this Agreement other than in accordance
with the terms of Section 4.6 or Section 6.3. At any time, the Representative may resign (in which case the Acting
Holders shall promptly appoint a successor Representative (reasonably accept to Parent)) and may assign any of its rights or obligations
under this Agreement (or this Agreement in its entirety) to any third party (reasonably acceptable to Parent) to serve as a successor
Representative, provided that such assignee executes a written joinder to this Agreement assuming the rights and duties of the
Representative. The immunities and rights to indemnification granted to the Representative Group hereunder shall survive the resignation
or removal of the Representative or any member of the Advisory Group and the Closing and/or any termination of this Agreement. Certain
Holders have entered into an engagement agreement (the “Representative Engagement Agreement”) with the Representative
to provide direction to the Representative in connection with its services under this Agreement and the Representative Engagement Agreement
(such Holders, including their individual representatives, collectively hereinafter referred to as the “Advisory Group”).
Neither the Representative nor its members, managers, directors, officers, contractors, agents and employees nor any member of the Advisory
Group (collectively, the “Representative Group”) will incur liability of any kind to the Holders with respect to any
action or omission in connection with the acceptance or administration of the Representative’s responsibilities hereunder or under
the Representative Engagement Agreement, including any by the Representative in connection with the Representative’s services in
connection with this Agreement, except in the event and only to the extent of liability directly resulting from the Representative’s
bad faith, gross negligence, fraud or willful misconduct.
Section
4.6 Additional Covenants.
(a) During
the Disposition Period, Purchaser shall use commercially reasonable efforts to either enter into one or more Disposition Agreements during
the Disposition Period or to achieve the Development Milestone; provided that the foregoing shall not (i) require Purchaser to actively
solicit interest or proposals from third parties regarding a Disposition or (ii) constitute a guarantee by Purchaser that it will enter
into a Disposition Agreement or achieve the Development Milestone. The assessment of commercially reasonable efforts will take
into account all relevant factors, including Parent’s resources, business plan(s), and/or priorities. It is understood that
there is no minimum set of activities required to comply with this commercially reasonable efforts standard and that instead the activities
required by this commercially reasonable efforts standard may change from time to time based upon then-current scientific, business,
legal, financial, and other considerations.
(b) In
the event that Purchaser desires to consummate a Change of Control prior to the later of the Development CVR Payment Expiration Date
or the Cash CVR Payment Expiration Date, Purchaser or its successor, as applicable depending upon the structure of the Change of Control,
will cause the Person acquiring Purchaser (or the assets of Purchaser, as applicable) to assume Purchaser’s or its successor’s
(as applicable depending upon the structure of the Change of Control) obligations, duties and covenants under this Agreement, including
the obligation to pay the CVR Proceeds with respect to the Development Milestone (if applicable), and the CVR Proceeds with respect to
a Cash CVR Payment, as applicable. No later than five Business Days after to the consummation of any Change of Control, Purchaser will
deliver to the Rights Agent an Officer’s Certificate, stating that such Change of Control complies with this Section 4.6(b)
and that all conditions precedent herein relating to such transaction have been complied with.
(c) Until
such time as the Development CVR Payment Expiration Date occurs, (i) Purchaser shall, and shall cause its Subsidiaries to, maintain records
in the ordinary course of business pursuant to record-keeping procedures normally used by Purchaser and its Subsidiaries regarding its
activities (including its resources and efforts) with respect to entering into Disposition Agreements and (ii) to the extent Purchaser
licenses, sells, assigns or otherwise transfers intellectual property and other rights (including, without limitation, all data, marketing
authorizations and applications for marketing authorization), assets, rights, powers, privileges and Contracts, in each case, (A) held,
owned or entered into by Purchaser or its Subsidiaries immediately after the effective time of a relevant Disposition, and (B) necessary
for the production, development or sale of a CVR Product, Purchaser will require the licensee, purchaser, assignee, or transferee, as
applicable to provide the information necessary for Purchaser to comply with its obligations under this Agreement.
(d) Upon
the reasonable written request from the Representative, Parent will provide the Representative, (i) during the Disposition Period, (A)
a written update in reasonable detail describing the progress, status and anticipated trajectory of efforts in respect of any Dispositions
and (B) after the occurrence of a Disposition with respect to which CVR Proceeds may be owed, the anticipated timing of receiving payments
pursuant to the applicable Disposition Agreement, in each case up to one time in a fiscal quarter of each calendar year, and (ii) during
the period prior to the Cash CVR Payment Expiration Date, up to one time in a fiscal quarter of each calendar quarter, a written update
in reasonable detail describing the progress, and status of any Rain Litigation, including a detailed calculation of any Rain Litigation
Expenses incurred through the date of such request, unless doing so would reasonably be likely to jeopardize any privilege of Parent
or Rain regarding any such Rain Litigation (subject to such party using commercially reasonable efforts to develop and implement, and
cooperating in good faith with the other party in developing and implementing, reasonable alternative arrangements to provide such other
party with such information).
(e) Prior
to a final, non-appealable determination on a motion to dismiss on any Rain Litigation, Parent or Rain shall not admit any liability
with respect to, or settle, compromise or discharge, or offer to settle, compromise or discharge any Rain Litigation without the Representative’s
prior written consent, except as set forth on Schedule 4.6(e) attached hereto. Notwithstanding anything to the contrary herein,
other than any consent required under this Section 4.6(e), Parent shall control the defense of any Rain Litigation.
ARTICLE
V
AMENDMENTS
Section
5.1 Amendments without Consent of Holders.
(a) Without
the consent of any Holders or the Rights Agent, the Representative, Parent and Purchaser, at any time and from time to time, may enter
into one or more amendments hereto, for any of the following purposes:
(i) to
evidence the succession of another Person to Parent or Purchaser and the assumption by any such successor of the covenants of Parent
or Purchaser herein as provided in Section 6.3;
(ii) to
add to the covenants of Parent and Purchaser such further covenants, restrictions, conditions or provisions as the Representative, Parent,
and Purchaser will consider to be for the protection of the Holders; provided that, in each case, such provisions do not adversely
affect the interests of the Holders;
(iii) to
cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with any other provision herein,
or to make any other provisions with respect to matters or questions arising under this Agreement; provided that, in each case,
such provisions do not adversely affect the interests of the Holders;
(iv) as
may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act of 1933, as amended,
or the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, and to ensure that the CVRs
are not subject to any similar registration or prospectus requirement under applicable securities Laws outside of the United States;
provided that, in each case, such provisions do not adversely affect the interests of the Holders;
(v) to
evidence the succession of another Person as a successor Rights Agent or the Representative and the assumption by any such successor
of the covenants and obligations of the Rights Agent or the Representative, as applicable, herein in accordance with Section
3.3 and Section 3.4;
(vi) as
may be necessary to ensure that Parent complies with applicable Law, as determined by Parent after being advised by Parent’s outside
counsel that such amendment is necessary for such purposes; or
(vii) any
other amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, unless such addition, elimination
or change is adverse to the interests of the Holders.
(b) Without
the consent of any Holders, Parent and Purchaser, the Rights Agent, in its sole and absolute discretion, at any time and from time to
time, may enter into one or more amendments hereto, to reduce the number of CVRs, in the event any Holder agrees to renounce and abandon
such Holder’s rights under this Agreement in accordance with Section 2.7.
(c) Promptly
after the execution by the Representative, Parent, Purchaser and/or the Rights Agent (as applicable) of any amendment pursuant to the
provisions of this Section 5.1, Parent shall mail (or cause the Rights Agent to mail) a notice thereof by first class mail
to the Holders at their addresses as they appear on the CVR Register, setting forth such amendment.
Section
5.2 Amendments with Consent of Holders.
(a) Subject
to Section 5.1 (which amendments pursuant to Section 5.1 may be made without the consent of the Holders), with
the consent of the Advisory Group, the Representative, Parent and Purchaser may, without the consent of the Rights Agent, enter into
one or more amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, even if such addition,
elimination or change is materially adverse to the interests of the Holders.
(b) Promptly
after the execution by Parent, Purchaser and the Representative of any amendment pursuant to the provisions of this Section 5.2,
Parent will mail (or cause the Rights Agent to mail) a notice thereof by first class mail to the Holders at their addresses as they appear
on the CVR Register, setting forth such amendment.
Section
5.3 Execution of Amendments. In executing any amendment permitted by this ARTICLE V, the Rights Agent will be entitled
to receive, and will be fully protected in relying upon, an opinion of counsel selected by Parent stating that the execution of such
amendment is authorized or permitted by this Agreement. The Rights Agent may, but is not obligated to, enter into any such amendment
that affects the Rights Agent’s own rights, privileges, covenants or duties under this Agreement or otherwise.
Section
5.4 Effect of Amendments. Upon the execution of any amendment under this ARTICLE V, this Agreement will be modified
in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. Notwithstanding
anything in this Agreement to the contrary, the Rights Agent and the Representative shall not be required to execute any supplement or
amendment to this Agreement that it has determined would adversely affect its own rights, duties, obligations or immunities under this
Agreement or, with respect to the Representative, the rights, duties, obligations or immunities of the Holders under this Agreement.
No supplement or amendment to this Agreement shall be effective unless duly executed by the Rights Agent and the Representative.
ARTICLE
VI
Other provisions of general application.
Section
6.1 Notice. Any notice or other communication required or permitted hereunder shall be in writing and shall be deemed given
when delivered in Person or by email, or when sent by overnight courier, or three Business Days after being sent by registered or certified
mail (postage prepaid, return receipt requested), provided that with respect to notices delivered to the Representative, such notices
must be delivered solely via email, as follows:
If
to the Rights Agent, to it at:
Equiniti
Trust Company, LLC
48
Wall Street, 22nd Floor
New
York, NY 10005
Attention:
Reorg Department
Email:
ReorgRM@equiniti.com
If
to the Representative, to it at:
Fortis
Advisors LLC
Attention:
Notices Department (Project Plymouth)
Email:
notices@fortisrep.com
If
to Parent or Purchaser, to Parent at:
600
W. Chicago Ave., Suite 501
Chicago, IL 60654
Attention: Zach Malkin, Ryan Fukushima, Matt De Silva
E-mail: [***], [***], [***]
With
copies (which shall not constitute notice) to:
Goodwin
Procter LLP
100 Northern Avenue
Boston, MA 02210
Attention: Mitchell S. Bloom, Robert Masella, Jean A. Lee
Email: mbloom@goodwinlaw.com, rmasella@goodwinlaw.com, jeanlee@goodwinlaw.com
and
Gibson,
Dunn & Crutcher LLP
555 Mission Street, Suite 3000
San Francisco, CA 94105
Attention: Ryan A. Murr, Branden C. Berns
Email: rmurr@gibsondunn.com, bberns@gibsondunn.com
Any
party may specify a different address by giving notice in accordance with this Section 6.1.
Section
6.2 Notice to Holders. Where this Agreement provides for notice to Holders, such notice will be sufficiently given (unless
otherwise herein expressly provided) if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at
the Holder’s address as it appears in the CVR Register, not later than the latest date, and not earlier than the earliest date,
if any, prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such
notice, nor any defect in any notice so mailed, to any particular Holder will affect the sufficiency of such notice with respect to other
Holders.
Section
6.3 Successors and Assigns. Parent and Purchaser may assign any or all of its rights, interests and obligations hereunder in
its sole discretion and without the consent of any other party, (i)i) to any controlled Affiliate of Parent, but only for so long as
it remains a controlled Affiliate of Parent, (ii)ii) in compliance with Section 4.6(a), (iii) to any acquiror of the CVR Products,
or (iv) otherwise with the prior written consent of the Acting Holders (such consent not to be unreasonably withheld, conditioned or
delayed), any other Person (any permitted assignee under clauses (i), (ii), (iii) or (iv), an “Assignee”),
in each case provided that the Assignee agrees to assume and be bound by all of the terms of this Agreement. Any Assignee may
thereafter assign any or all of its rights, interests and obligations hereunder in the same manner as Parent or Purchaser pursuant to
the prior sentence. In connection with any assignment to an Assignee described in this Section 6.3, each of Parent or Purchaser,
as applicable, (and the other assignor) shall agree to remain liable for the performance by each Assignee (and such other assignor, if
applicable) of all obligations of Parent or Purchaser, as applicable, hereunder with such Assignee substituted for Parent or Purchaser,
as applicable, under this Agreement. This Agreement will be binding upon, inure to the benefit of and be enforceable by each of Parent’s
successors and each Assignee and each of Purchaser’s successors and each Assignee, as applicable. Subject to compliance with the
requirements set forth in this Section 6.3 relating to assignments, this Agreement shall not restrict Parent’s, Purchaser’s,
any Assignee’s or any of their respective successors’ ability to merge or consolidate with, or sell, issue or dispose of
its stock or other equity interests or assets to, any other Person. Each of Parent’s successors and Assignees and each of Purchaser’s
successors and Assignees, as applicable, shall expressly assume by an instrument supplemental hereto, executed and delivered to the Rights
Agent (with a copy to the Representative), the due and punctual payment of the CVR Proceeds and the due and punctual performance and
observance of all of the covenants and obligations of this Agreement to be performed or observed by Parent or Purchaser, as applicable.
The Rights Agent may not assign this Agreement without the Representative’s written consent; provided that such written
consent shall not be unreasonably withheld, conditioned or delayed. Any attempted assignment of this Agreement or any such rights in
violation of this Section 6.3 shall be void and of no effect.
Section
6.4 Benefits of Agreement. Nothing in this Agreement, express or implied, will give to any Person (other than the Rights Agent
and its permitted successors and assigns, the Representative, Parent, Parent’s successors and Assignees, Purchaser, Purchaser’s
successors and Assignees, the Holders and the Holders’ successors and assigns pursuant to a Permitted CVR Transfer) any benefit
or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants
and provisions being for the sole benefit of the foregoing. The rights of Holders and their successors and assigns pursuant to Permitted
CVR Transfers are limited to those expressly provided in this Agreement and any remedies available to any Holder shall be limited as
set forth herein and shall expressly exclude equity remedies (including specific performance). Except for the rights of the Rights Agent
and the Representative set forth herein, the Acting Holders will have the sole right, on behalf of all Holders, by virtue of or under
any provision of this Agreement, to institute any action or proceeding with respect to this Agreement, and no individual Holder or other
group of Holders will be entitled to exercise such rights. Reasonable expenditures incurred by such Holders in connection with any enforcement
action hereunder may be deducted from any damages or settlement obtained prior to the distribution of any remainder to Holders generally.
Holders acting pursuant to this provision on behalf of all Holders shall have no liability to the other Holders for such actions.
Section
6.5 Governing Law; Jurisdiction; Waiver of Jury Trial.
(a) This
Agreement, the CVRs and all disputes or controversies arising out of or relating to this Agreement or the transactions contemplated hereby
shall be governed by, and construed in accordance with, the internal Laws of the State of Delaware, without regard to the Laws of any
other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware.
(b) Each
of the parties hereto irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement brought by
any party or its Affiliates against any other party or its Affiliates shall be brought and determined in the Court of Chancery of the
State of Delaware, provided, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then
any such legal action or proceeding may be brought in any federal court located in the State of Delaware. Each of the parties hereby
irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally,
with regard to any such action or proceeding arising out of or relating to this Agreement and the transactions contemplated hereby. Each
of the parties agrees not to commence any action, suit or proceeding relating thereto except in the courts described above in Delaware,
other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in Delaware
as described herein. Each of the parties further agrees that notice as provided herein shall constitute sufficient service of process
and the parties further waive any argument that such service is insufficient. Each of the parties hereby irrevocably and unconditionally
waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out
of or relating to this Agreement or the transactions contemplated hereby, (i) any claim that it is not personally subject to the
jurisdiction of the courts in Delaware as described herein for any reason, (ii) that it or its property is exempt or immune from
jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior
to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (iii) that (A) the suit, action
or proceeding in any such court is brought in an inconvenient forum, (B) the venue of any suit, action or proceeding brought in
such court is improper or (C) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.
(c) EACH
OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING
OUT OF OR RELATING TO THIS AGREEMENT, THE CVRS OR THE TRANSACTIONS CONTEMPLATED HEREBY.
Section
6.6 Severability. Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such
manner as to be effective and valid under applicable Law, but if any provision or portion of any provision of this Agreement is held
to be invalid, illegal or unenforceable in any respect under any applicable Law or rule in any jurisdiction, such invalidity, illegality
or unenforceability shall not affect any other provision or portion of any provision in such jurisdiction, and this Agreement shall be
reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision
had never been contained herein.
Section
6.7 Counterparts and Signature. This Agreement may be executed in two or more counterparts (including by an electronic scan
delivered by electronic mail), each of which shall be deemed an original but all of which together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each of the parties hereto and delivered to the other party,
it being understood that the parties need not sign the same counterpart. The exchange of a fully executed Agreement (in counterparts
or otherwise) by .PDF shall be sufficient to bind the parties to the terms and conditions of this Agreement.
Section
6.8 Termination. This Agreement will be terminated and of no force or effect, the parties hereto will have no liability hereunder
(other than with respect to monies due and owing by Parent or Purchaser to the Rights Agent and/or the Representative), and no payments
will be required to be made, upon the earliest to occur of (a) the mailing by the Rights Agent to the address of each Holder as reflected
in the CVR Register of all CVR Payment Amounts (if any) required to be paid under the terms of this Agreement, (b) the delivery of a
written notice of termination duly executed by Parent, Purchaser and the Acting Holders or (c) the later of the Development CVR Payment
Expiration Date and the Cash CVR Payment Expiration Date; provided, that in any event, this Agreement shall be terminated and of no force
or effect after ten (10) years from the date hereof. The termination of this Agreement will not affect or limit the right of Holders
to receive the CVR Payment Amounts under Section 2.4 to the extent earned prior to the termination of this Agreement and the provisions
applicable thereto will survive the expiration or termination of this Agreement until such CVR Payment Amounts have been made, if applicable.
Upon termination of this Agreement pursuant to this Section 6.8, all CVRs issued shall be automatically cancelled and forfeited
by the Holders without any consideration or payment therefor. For the avoidance of doubt and notwithstanding anything to the contrary,
nothing herein shall terminate or otherwise negatively affect any of the rights or remedies of the Representative Group with respect
to the Holders pursuant to this Agreement or otherwise.
Section
6.9 Entire Agreement. This Agreement and the Merger Agreement (including the schedules, annexes and exhibits thereto and the
documents and instruments referred to therein) contain the entire understanding of the parties hereto and thereto with reference to the
transactions and matters contemplated hereby and thereby and supersede all prior agreements, written or oral, among the parties with
respect hereto and thereto. If and to the extent that any provision of this Agreement is inconsistent or conflicts with the Merger Agreement,
this Agreement shall govern and be controlling.
Section
6.10 Further Assurances. Parent agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed,
acknowledged and delivered, all such further and other acts, instruments and assurances as may reasonably be required by the Rights Agent
or the Representative for the carrying out or performing by the Rights Agent or the Representative of the provisions of this Agreement.
Section
6.11 Confidentiality. The Rights Agent, the Representative and the Parent agree that all books, records, information and data
pertaining to the business of the other party, including inter alia, personal, non-public Holder information and any information required
to be provided pursuant to this Agreement, which are exchanged or received pursuant to the negotiation or the carrying out of this Agreement
including the fees for services set forth in the attached schedule (collectively “Confidential Information”) shall
remain confidential, and shall not be voluntarily disclosed to any other person (provided, however, that the Rights Agent,
the Representative or Parent may disclose relevant aspects of the other party’s Confidential Information to its officers, Affiliates,
agents, subcontractors, employees and representatives to the extent reasonably necessary to perform its duties and obligations under
this Agreement and such disclosure is not prohibited by applicable Law and, for the avoidance of doubt, the Representative may disclose
Confidential Information to the Representative Group), except as may be required by a valid order of an arbitration panel, court or Governmental
Entity of competent jurisdiction or is otherwise required by Law or regulation, including SEC or Nasdaq rules and regulations, or pursuant
to subpoenas from state or federal government authorities (e.g., in divorce and criminal actions). “Confidential Information”
does not include information that is (a) already known to the other party or its Affiliates at the time of the disclosure; (b) publicly
known at the time of the disclosure or becomes publicly known through no wrongful act or failure to act of the other party in breach
of this Section 6.11; (c) subsequently disclosed to the other party or its Affiliates on a non-confidential basis by
a third party not having a confidential relationship with the owner and which rightfully acquired such information; or (d) independently
developed by one party without access to the Confidential Information of the other.
Section
6.12 Legal Holiday. In the event that the CVR Payment Date shall not be a Business Day, then, notwithstanding any provision
of this Agreement to the contrary, any payment required to be made in respect of the CVRs on such date need not be made on such date,
but may be made on the next succeeding Business Day with the same force and effect as if made on the CVR Payment Date.
Section
6.13 Obligations of Parent. Parent shall ensure that Purchaser, and Purchaser shall ensure that Parent, duly perform, satisfy
and discharge each of the covenants, obligations and liabilities applicable to such party under this Agreement, and Parent shall be jointly
and severally liable with Purchaser for the performance and satisfaction of each of said covenants, obligations and liabilities. References
to Purchaser herein apply to the surviving corporation of the Merger with Rain from and after the Effective Time.
Section
6.14 Additional Agreements Relating to Representative. The Holders shall indemnify, defend and hold harmless the Representative
Group from and against any and all losses, claims, damages, liabilities, fees, costs, expenses (including fees, disbursements and costs
of counsel and other skilled professionals and in connection with seeking recovery from insurers), judgments, fines or amounts paid in
settlement (collectively, the “Representative Expenses”) incurred without gross negligence or willful misconduct on
the part of the Representative and arising out of or in connection with the acceptance or administration of its duties hereunder or under
the Representative Engagement Agreement. Such Representative Expenses may be recovered first, from the Expense Fund, second, from any
distribution of CVR Proceeds or other amount otherwise distributable to the Holders under this Agreement at the time of distribution,
and third, directly from the Holders. The Holders acknowledge that the Representative shall not be required to expend or risk its own
funds or otherwise incur any financial liability in the exercise or performance of any of its powers, rights, duties or privileges or
pursuant to this Agreement, the Representative Engagement Agreement or the transactions contemplated hereby or thereby. Furthermore,
the Representative shall not be required to take any action unless the Representative has been provided with funds, security or indemnities
which, in its determination, are sufficient to protect the Representative against the costs, expenses and liabilities which may be incurred
by the Representative in performing such actions. The Representative shall be entitled to: (a) rely upon any applicable CVR Register,
CVR Payment Notice and any document provided by or on behalf of the Advisory Group or Rain relating to the allocation of payments or
otherwise relating to the Holders, (b) rely upon any signature believed by it to be genuine, and (c) reasonably assume that a signatory
has proper authorization to sign on behalf of the applicable Holder or other party.
Section
6.15 Expense Fund. Upon the Closing, Parent shall, on behalf of the Holders, wire to the Representative $50,000 (the “Expense
Fund Amount”). The Expense Fund Amount shall be held by the Representative in a segregated client account and shall be used
(a) for the purposes of paying directly or reimbursing the Representative for any Representative Expenses incurred pursuant to this Agreement
or the Representative Engagement Agreement, or (b) as otherwise determined by the Advisory Group (the “Expense Fund”).
The Representative is not providing any investment supervision, recommendations or advice and shall have no responsibility or liability
for any loss of principal of the Expense Fund other than as a result of its gross negligence or willful misconduct. The Representative
is not acting as a withholding agent or in any similar capacity in connection with the Expense Fund and has no tax reporting or income
distribution obligations. The Holders will not receive any interest on the Expense Fund and assign to the Representative any such interest.
Subject to Advisory Group approval, the Representative may contribute funds to the Expense Fund from any CVR Proceeds or other amounts
otherwise distributable to the Holders. As soon as reasonably determined by the Representative that the Expense Fund is no longer required
to be withheld, the Representative shall distribute the remaining Expense Fund (if any) to the Rights Agent and/or Parent, as applicable,
for further distribution to the Holders.
[Remainder
of Page Left Blank Intentionally]
IN
WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by its duly authorized officers as of the
day and year first above written.
|
PATHOS AI, INC. |
|
|
|
|
By |
/s/ Ryan Fukushima |
|
Name: |
Ryan Fukushima |
|
Title: |
Chief Executive Officer |
IN
WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by its duly authorized officers as of the
day and year first above written.
|
wk merger sub,
inc. |
|
|
|
|
By |
/s/ Ryan Fukushima |
|
Name: |
Ryan Fukushima |
|
Title: |
Chief Executive Officer |
IN
WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by its duly authorized officers as of the
day and year first above written.
|
EQUINITI TRUST COMPANY, LLC |
|
|
|
|
By |
/s/ Michael Legregin |
|
Name |
Michael Legregin |
|
Title |
Senior Vice President, Corporate
Actions |
IN
WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by its duly authorized officers as of the
day and year first above written.
|
FORTIS ADVISORS
LLC, solely in its capacity as Representative |
|
|
|
|
By |
/s/ Ryan Simkin |
|
Name: |
Ryan Simkin |
|
Title: |
Managing Director |
Rain Oncology Inc.8-K
Exhibit 3.1
FIFTH
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
RAIN ONCOLOGY INC.
| FIRST: | The name of this corporation shall be: Rain Oncology Inc. |
| SECOND: | Its registered office in the State of Delaware is to be located at: |
c/o Corporation Service Company, 251 Little
Falls Drive, Wilmington, DE 19808, County of New Castle, and its registered agent at such address is: The Corporation Service Company.
| THIRD: | The purpose or purposes of the corporation shall be: |
To carry on any and all business and to engage
in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware.
| FOURTH: | The total number of shares of stock which this corporation is authorized to issue is: |
One Hundred (100) shares of Common Stock,
par value $0.001 per share. All shares of Common Stock shall be uncertificated.
| FIFTH: | In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board of Directors is expressly
authorized to adopt, amend or repeal the by-laws of the corporation. |
| SIXTH: | Elections of directors need not be by written ballot unless the by-laws of the corporation shall so provide. |
| SEVENTH: | To the fullest extent permitted by the DGCL as the same exists or as may hereafter be amended,
no director of the corporation shall be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary
duty as a director. Any amendment, alteration or repeal of this Article that adversely affects any right of a director shall be prospective
only and shall not limit or eliminate any such right with respect to any proceeding involving any occurrence or alleged occurrence of
any action or omission to act that took place prior to such amendment, alteration or repeal. |
| EIGHTH: | The corporation reserves the right at any time, and from time to time, to amend, alter, change or repeal any provision contained
in this Certificate of Incorporation, and to add or insert other provisions authorized by the laws of the State of Delaware at the
time in force, in the manner now or hereafter prescribed by law; and all rights, preferences and privileges of whatsoever nature
conferred upon stockholders, directors or any other persons whomsoever by and
pursuant to this Certificate of Incorporation in its present form or as hereafter amended are granted subject to the rights reserved in
this Article EIGHTH. |
| NINTH: | Whenever a compromise or arrangement is proposed between this corporation and its creditors or any class of them and/or between this
corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application
in a summary way of this corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed
for this corporation under the provisions of Section 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution
or of any receiver or receivers appointed for this corporation under the provisions of Section 279 of Title 8 of the Delaware Code
order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this corporation, as the
case may be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths in value of the
creditors or class of creditors, and/or of the stockholders or class of stockholders of this corporation, as the case may be, agree to
any compromise or arrangement and to any reorganization of this corporation as consequence of such compromise or arrangement, the said
compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be
binding on all the creditors or class of creditors, and/or on all the stockholders or class of stockholders, of this corporation, as the
case may be, and also on this corporation. |
Rain Oncology Inc.8-K
Exhibit 3.2
AMENDED AND RESTATED
BY-LAWS
of
Rain Oncology Inc.
(the “Corporation”)
1.
Stockholders
(a)
Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place,
date and time as shall be designated by the Board of Directors. Any other proper business may be transacted at the annual meeting. If
no date for the annual meeting is established or said meeting is not held on the date established as provided above, a special meeting
in lieu thereof may be held or there may be action by written consent of the stockholders on matters to be voted on at the annual meeting,
and such special meeting or written consent shall have for the purposes of these By-laws or otherwise all the force and effect of
an annual meeting.
(b)
Special Meetings. Special meetings of stockholders may be called by the Chief Executive Officer, if one is elected, or,
if there is no Chief Executive Officer, a President, or by the Board of Directors, but such special meetings may not be called by any
other person or persons. The call for the meeting shall state the place, date, hour and purposes of the meeting. Only the purposes specified
in the notice of special meeting shall be considered or dealt with at such special meeting.
(c)
Notice of Meetings. Whenever stockholders are required or permitted to take any action at a meeting, a notice stating the
place, if any, date and hour of the meeting, the means of remote communications, if any, by which stockholders and proxy holders may be
deemed to be present and vote at such meeting, and, in the case of a special meeting, the purpose or purposes of the meeting, shall be
given by the Secretary (or other person authorized by these By-laws or by law) not less than ten (10) nor more than sixty (60) days
before the meeting to each stockholder entitled to vote thereat and to each stockholder who, under the Certificate of Incorporation or
under these By-laws is entitled to such notice. If mailed, notice is given when deposited in the mail, postage prepaid, directed to
such stockholder at such stockholder’s address as it appears in the records of the Corporation. Without limiting the manner by which
notice otherwise may be effectively given to stockholders, any notice to stockholders may be given by electronic transmission in the manner
provided in Section 232 of the Delaware General Corporation Law (the “DGCL”).
If a meeting is adjourned to another time or
place, notice need not be given of the adjourned meeting if the time and place, if any, and the means of remote communications, if any,
by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the
meeting at which the adjournment is taken, except that if the adjournment is for more than thirty (30) days, or if after the adjournment
a new record date is fixed for the adjourned meeting, notice of the adjourned meeting shall be given to each stockholder of record entitled
to vote at the meeting.
(d)
Quorum. The holders of a majority in interest of all stock issued, outstanding and entitled to vote at a meeting, present
in person or represented by proxy, shall constitute a quorum. Any meeting may be adjourned from time to time by a majority of the votes
properly cast upon the question, whether or not a quorum is present. The stockholders present at a duly constituted meeting may continue
to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum.
(e)
Voting and Proxies. Except as otherwise provided by the Certificate of Incorporation or by law, each stockholder entitled
to vote at any meeting of stockholders shall be entitled to one vote for each share of stock held by such stockholder which has voting
power upon the matter in question. Each stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to
corporate action in writing without a meeting may authorize another person or persons to act for such stockholder by either written proxy
or by a transmission permitted by Section 212(c) of the DGCL, but no proxy shall be voted or acted upon after three years from its date,
unless the proxy provides for a longer period or is irrevocable and coupled with an interest. Proxies shall be filed with the Secretary
of the meeting, or of any adjournment thereof. Except as otherwise limited therein, proxies shall entitle the persons authorized thereby
to vote at any adjournment of such meeting.
(f)
Action at Meeting. When a quorum is present, any matter before the meeting shall be decided by vote of the holders of a
majority of the shares of stock voting on such matter except where a larger vote is required by law, by the Certificate of Incorporation
or by these By-laws. Any election of directors by stockholders shall be determined by a plurality of the votes cast, except where
a larger vote is required by law, by the Certificate of Incorporation or by these By-laws. The Corporation shall not directly or indirectly
vote any share of its own stock; provided, however, that the Corporation may vote shares which it holds in a fiduciary capacity to the
extent permitted by law.
(g)
Presiding Officer. Meetings of stockholders shall be presided over by the Chairman of the Board, if one is elected, or in
his or her absence, the Vice Chairman of the Board, if one is elected, or if neither is elected or in their absence, a President. The
Board of Directors shall have the authority to appoint a temporary presiding officer to serve at any meeting of the stockholders if the
Chairman of the Board, the Vice Chairman of the Board or a President is unable to do so for any reason.
(h)
Conduct of Meetings. The Board of Directors may adopt by resolution such rules and regulations for the conduct of the meeting
of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board
of Directors, the presiding officer of any meeting of stockholders shall have the right and authority to prescribe such rules, regulations
and procedures and to do all such acts as, in the judgment of such chairman, are appropriate for the proper conduct of the meeting. Such
rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the presiding officer of the meeting, may
include, without limitation, the following: (i) the establishment of an agenda or order of business for the meeting; (ii) rules and procedures
for maintaining order at the meeting and the safety of those present; (iii) limitations on attendance at or participation in the meeting
to stockholders of record of the Corporation, their duly authorized and constituted proxies or such other persons as the chairman of
the meeting shall determine; (iv) restrictions on entry to the meeting after the time fixed for the commencement thereof; and (v) limitations
on the time allotted to questions or comments by participants. Unless and to the extent determined by the Board of Directors or the presiding
officer of the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure.
(i)
Action without a Meeting. Unless otherwise provided in the Certificate of Incorporation, any action required or permitted
by law to be taken at any annual or special meeting of stockholders, may be taken without a meeting, without prior notice and without
a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having
not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled
to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered office, by hand or by certified
mail, return receipt requested, or to the Corporation's principal place of business or to the officer of the Corporation having custody
of the minute book. Every written consent shall bear the date of signature and no written consent shall be effective unless, within sixty
(60) days of the earliest dated consent delivered pursuant to these By-laws, written consents signed by a sufficient number of stockholders
entitled to take action are delivered to the Corporation in the manner set forth in these By-laws. Prompt notice of the taking of
the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented
in writing.
(j)
Stockholder Lists. The officer who has charge of the stock ledger of the Corporation shall prepare and make, at least ten
(10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical
order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Nothing contained
in this Section 1(j) shall require the Corporation to include electronic mail addresses or other electronic contact information on such
list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, for a period of at least
ten (10) days prior to the meeting in the manner provided by law. The list shall also be open to the examination of any stockholder during
the whole time of the meeting as provided by law.
2.
Directors
(a)
Powers. The business of the Corporation shall be managed by or under the direction of a Board of Directors who may exercise
all the powers of the Corporation except as otherwise provided by law, by the Certificate of Incorporation or by these By-laws. In
the event of a vacancy in the Board of Directors, the remaining directors, except as otherwise provided by law, may exercise the powers
of the full Board until the vacancy is filled.
(b)
Number and Qualification. Unless otherwise provided in the Certificate of Incorporation or in these By-laws, the number
of directors which shall constitute the whole board shall be determined from time to time by resolution of the Board of Directors. Directors
need not be stockholders.
(c)
Vacancies; Reduction of Board. A majority of the directors then in office, although less than a quorum, or a sole remaining
Director, may fill vacancies in the Board of Directors occurring for any reason and newly created directorships resulting from any increase
in the authorized number of directors. In lieu of filling any vacancy, the Board of Directors may reduce the number of directors.
(d)
Tenure. Except as otherwise provided by law, by the Certificate of Incorporation or by these By-laws, directors shall
hold office until their successors are elected and qualified or until their earlier resignation or removal. Any director may resign at
any time upon notice given in writing or by electronic transmission to the Corporation. Such resignation shall be effective upon receipt
unless it is specified to be effective at some other time or upon the happening of some other event.
(e)
Removal. To the extent permitted by law, a director may be removed from office with or without cause by vote of the holders
of a majority of the shares of stock entitled to vote in the election of directors.
(f)
Meetings. Regular meetings of the Board of Directors may be held without notice at such time, date and place as the Board
of Directors may from time to time determine. Special meetings of the Board of Directors may be called, orally or in writing, by the Chief
Executive Officer, if one is elected, or, if there is no Chief Executive Officer, the President, or by two or more Directors, designating
the time, date and place thereof. Directors may participate in meetings of the Board of Directors by means of conference telephone or
other communications equipment by means of which all directors participating in the meeting can hear each other, and participation in
a meeting in accordance herewith shall constitute presence in person at such meeting.
(g)
Notice of Meetings. Notice of the time, date and place of all special meetings of the Board of Directors shall be given
to each director by the Secretary, or Assistant Secretary, or in case of the death, absence, incapacity or refusal of such persons, by
the officer or one of the directors calling the meeting. Notice shall be given to each director in person, by telephone, or by facsimile,
electronic mail or other form of electronic communications, sent to such director’s business or home address at least twenty-four
(24) hours in advance of the meeting, or by written notice mailed to such director’s business or home address at least forty-eight
(48) hours in advance of the meeting.
(h)
Quorum. At any meeting of the Board of Directors, the greater of (a) a majority of the directors then in office at the time
quorum is to be determined and (b) one-third of the total number of directors fixed pursuant to Section 2(b) of these By-laws shall constitute
a quorum for the transaction of business. Less than a quorum may adjourn any meeting from time to time and the meeting may be held as
adjourned without further notice.
(i)
Action at Meeting. At any meeting of the Board of Directors at which a quorum is present, unless otherwise provided in
the following sentence, a majority of the directors present may take any action on behalf of the Board of Directors, unless a larger number
is required by law, by the Certificate of Incorporation or by these By-laws. So long as there are two (2) or fewer Directors, any
action to be taken by the Board of Directors shall require the approval of all Directors.
(j)
Action by Consent. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken without
a meeting if all members of the Board of Directors consent thereto in writing or by electronic transmission, and the writing or writings
or electronic transmission or transmissions are filed with the records of the meetings of the Board of Directors. Such filing shall be
in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic
form.
(k)
Committees. The Board of Directors may, by resolution passed by a majority of the whole Board of Directors, establish one
or more committees, each committee to consist of one or more directors. The Board of Directors may designate one or more directors as
alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence
or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting,
whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at
the meeting in the place of any such absent or disqualified member.
Any such committee, to the extent permitted
by law and to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority
of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation
to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to the following:
(i) approving or adopting, or recommending to the stockholders, any action or matter expressly required by the DGCL to be submitted to
stockholders for approval or (ii) adopting, amending or repealing any provision of these By-laws.
Except as the Board of Directors may otherwise
determine, any such committee may make rules for the conduct of its business, but in the absence of such rules its business shall be conducted
so far as possible in the same manner as is provided in these By-laws for the Board of Directors. All members of such committees shall
hold their committee offices at the pleasure of the Board of Directors, and the Board may abolish any committee at any time.
3.
Officers
(a)
Enumeration. The officers of the Corporation shall consist of one or more Presidents (who, if there is more than one, shall
be referred to as Co-Presidents), a Treasurer, a Secretary, and such other officers, including, without limitation, a Chief Executive
Officer and one or more Vice Presidents (including Executive Vice Presidents or Senior Vice Presidents), Assistant Vice Presidents, Assistant
Treasurers and Assistant Secretaries, as the Board of Directors may determine. The Board of Directors may elect from among its members
a Chairman of the Board and a Vice Chairman of the Board.
(b)
Election. The Presidents, Treasurer and Secretary shall be elected annually by the Board of Directors at their first meeting
following the annual meeting of stockholders. Other officers may be chosen by the Board of Directors at such meeting or at any other meeting.
(c)
Qualification. No officer need be a stockholder or Director. Any two or more offices may be held by the same person. Any
officer may be required by the Board of Directors to give bond for the faithful performance of such officer’s duties in such amount
and with such sureties as the Board of Directors may determine.
(d)
Tenure. Except as otherwise provided by the Certificate of Incorporation or by these By-laws, each of the officers of
the Corporation shall hold office until the first meeting of the Board of Directors following the next annual meeting of stockholders
and until such officer’s successor is elected and qualified or until such officer’s earlier resignation or removal. Any officer
may resign by delivering his or her written resignation to the Corporation, and such resignation shall be effective upon receipt unless
it is specified to be effective at some other time or upon the happening of some other event.
(e)
Removal. The Board of Directors may remove any officer with or without cause by a vote of a majority of the directors then
in office.
(f)
Vacancies. Any vacancy in any office may be filled for the unexpired portion of the term by the Board of Directors.
(g)
Chairman of the Board and Vice Chairman. Unless otherwise provided by the Board of Directors, the Chairman of the Board
of Directors, if one is elected, shall preside, when present, at all meetings of the stockholders and the Board of Directors. The Chairman
of the Board shall have such other powers and shall perform such duties as the Board of Directors may from time to time designate.
Unless otherwise provided by the Board of Directors,
in the absence of the Chairman of the Board, the Vice Chairman of the Board, if one is elected, shall preside, when present, at all meetings
of the stockholders and the Board of Directors. The Vice Chairman of the Board shall have such other powers and shall perform such duties
as the Board of Directors may from time to time designate.
(h)
Chief Executive Officer. The Chief Executive Officer, if one is elected, shall have such powers and shall perform such duties
as the Board of Directors may from time to time designate.
(i)
Presidents. The Presidents shall, subject to the direction of the Board of Directors, each have general supervision and
control of the Corporation’s business and any action that would typically be taken by a President may be taken by any Co-President.
If there is no Chairman of the Board or Vice Chairman of the Board, a President shall preside, when present, at all meetings of stockholders
and the Board of Directors. The Presidents shall have such other powers and shall perform such duties as the Board of Directors may from
time to time designate.
(j)
Vice Presidents and Assistant Vice Presidents. Any Vice President (including any Executive Vice President or Senior Vice
President) and any Assistant Vice President shall have such powers and shall perform such duties as the Board of Directors may from time
to time designate.
(k)
Treasurer and Assistant Treasurers. The Treasurer shall, subject to the direction of the Board of Directors, have general
charge of the financial affairs of the Corporation and shall cause to be kept accurate books of account. The Treasurer shall have custody
of all funds, securities, and valuable documents of the Corporation, except as the Board of Directors may otherwise provide. The Treasurer
shall have such other powers and shall perform such duties as the Board of Directors may from time to time designate.
Any Assistant Treasurer shall have such powers
and perform such duties as the Board of Directors may from time to time designate.
(l)
Secretary and Assistant Secretaries. The Secretary shall record the proceedings of all meetings of the stockholders and
the Board of Directors (including committees of the Board) in books kept for that purpose. In the absence of the Secretary from any such
meeting an Assistant Secretary, or if such person is absent, a temporary secretary chosen at the meeting, shall record the proceedings
thereof. The Secretary shall have charge of the stock ledger (which may, however, be kept by any transfer or other agent of the Corporation)
and shall have such other duties and powers as may be designated from time to time by the Board of Directors.
Any Assistant Secretary shall have such powers
and perform such duties as the Board of Directors may from time to time designate.
(m)
Other Powers and Duties. Subject to these By-laws, each officer of the Corporation shall have in addition to the duties
and powers specifically set forth in these By-laws, such duties and powers as are customarily incident to such officer’s office,
and such duties and powers as may be designated from time to time by the Board of Directors.
4.
Capital Stock
(a)
Certificates of Stock. Each stockholder shall be entitled to a certificate of the capital stock of the Corporation in such
form as may from time to time be prescribed by the Board of Directors. Such certificate shall be signed by, or in the name of, the Corporation
by any two (2) authorized officers of the Corporation. Such signatures may be a facsimile. In case any officer, transfer agent or registrar
who has signed or whose facsimile signature has been placed on such certificate shall have ceased to be such officer, transfer agent
or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such
officer, transfer agent or registrar at the time of its issue. Every certificate for shares of stock which are subject to any restriction
on transfer and every certificate issued when the Corporation is authorized to issue more than one class or series of stock shall contain
such legend with respect thereto as is required by law. The Corporation shall be permitted to issue fractional shares.
(b)
Transfers. Subject to any restrictions on transfer, shares of stock may be transferred on the books of the Corporation by
the surrender to the Corporation or its transfer agent of the certificate therefor properly endorsed or accompanied by a written assignment
or power of attorney properly executed, with transfer stamps (if necessary) affixed, and with such proof of the authenticity of signature
as the Corporation or its transfer agent may reasonably require.
(c)
Record Holders. Except as may otherwise be required by law, by the Certificate of Incorporation or by these By-laws,
the Corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes,
including the payment of dividends and the right to vote with respect thereto, regardless of any transfer, pledge or other disposition
of such stock, until the shares have been transferred on the books of the Corporation in accordance with the requirements of these By-laws.
It shall be the duty of each stockholder to
notify the Corporation of such stockholder’s post office address.
(d)
Record Date. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting
of stockholders or any adjournment thereof, or to consent to corporate action in writing without a meeting, or entitled to receive payment
of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion
or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which shall
not precede the date on which it is established, and which shall not be more than sixty (60) nor less than ten (10) days before the date
of such meeting, more than ten (10) days after the date on which the record date for stockholder consent without a meeting is established,
nor more than sixty (60) days prior to any other action. In such case only stockholders of record on such record date shall be so entitled
notwithstanding any transfer of stock on the books of the Corporation after the record date.
If no record date is fixed, (i) the record
date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the
day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day
on which the meeting is held, (ii) the record date for determining stockholders entitled to consent to corporate action in writing
without a meeting, when no prior action by the Board of Directors is necessary, shall be the first date on which a signed written consent
setting forth the action taken or proposed to be taken is delivered to the Corporation by delivery to its registered office in this state,
to its principal place of business, or to an officer or agent of the Corporation having custody of the book in which proceedings of meetings
of stockholders are recorded, and (iii) the record date for determining stockholders for any other purpose shall be at the close
of business on the day on which the Board of Directors adopts the resolution relating thereto.
(e)
Lost Certificates. The Corporation may issue a new certificate of stock in the place of any certificate theretofore issued
by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate,
or his legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on
account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate.
5.
Indemnification
(a)
Definitions. For purposes of this Section 5:
| (i) | “Corporate Status” describes the status of a person
who is serving or has served (i) as a Director of the Corporation, (ii) as an Officer of the Corporation, (iii) as a Non-Officer
Employee of the Corporation, or (iv) as a director, partner, trustee, officer, employee or agent of any other corporation, partnership,
limited liability company, joint venture, trust, employee benefit plan, foundation, association, organization or other legal entity which
such person is or was serving at the request of the Corporation. For purposes of this Section 1(a), a Director, Officer or
Non-Officer Employee of the Corporation who is serving or has served as a director, partner, trustee, officer, employee or agent of a
Subsidiary shall be deemed to be serving at the request of the Corporation. Notwithstanding the foregoing, “Corporate Status”
shall not include the status of a person who is serving or has served as a director, officer, employee or agent of a constituent corporation
absorbed in a merger or consolidation transaction with the Corporation with respect to such person’s activities prior to said transaction,
unless specifically authorized by the Board of Directors or the stockholders of the Corporation; |
| (ii) | “Director” means any person who serves or has served
the Corporation as a director on the Board of Directors of the Corporation; |
| (iii) | “Disinterested Director” means, with respect to each
Proceeding in respect of which indemnification is sought hereunder, a Director of the Corporation who is not and was not a party to such
Proceeding; |
| (iv) | “Expenses” means all attorneys’ fees, retainers,
court costs, transcript costs, fees of expert witnesses, private investigators and professional advisors (including, without limitation,
accountants and investment bankers), travel expenses, duplicating costs, printing and binding costs, costs of preparation of demonstrative
evidence and other courtroom presentation aids and devices, costs incurred in connection with document review, organization, imaging
and computerization, telephone charges, postage, delivery service fees, and all other disbursements, costs or expenses of the type customarily
incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settling or otherwise participating
in, a Proceeding; |
| (v) | “Liabilities” means judgments, damages, liabilities,
losses, penalties, excise taxes, fines and amounts paid in settlement; |
| (vi) | “Non-Officer Employee” means any person who serves or
has served as an employee or agent of the Corporation, but who is not or was not a Director or Officer; |
| (vii) | “Officer” means any person who serves or has served
the Corporation as an officer of the Corporation appointed by the Board of Directors of the Corporation; |
| (viii) | “Proceeding” means any threatened, pending or completed
action, suit, arbitration, alternate dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding,
whether civil, criminal, administrative, arbitrative or investigative; and |
| (ix) | “Subsidiary” shall mean any corporation, partnership,
limited liability company, joint venture, trust or other entity of which the Corporation owns (either directly or through or together
with another Subsidiary of the Corporation) either (i) a general partner, managing member or other similar interest or (ii) (A) fifty
percent (50%) or more of the voting power of the voting capital equity interests of such corporation, partnership, limited liability
company, joint venture or other entity, or (B) fifty percent (50%) or more of the outstanding voting capital stock or other voting
equity interests of such corporation, partnership, limited liability company, joint venture or other entity. |
(b)
Indemnification of Directors and Officers. Subject to the operation of Section 5(d) of these By-laws, each Director
and Officer shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the DGCL, as the same exists
or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to
provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), and to the extent
authorized in this Section 5(b).
(i)
Actions, Suits and Proceedings Other than By or In the Right of the Corporation. Each Director and Officer shall be indemnified
and held harmless by the Corporation against any and all Expenses and Liabilities that are incurred or paid by such Director or Officer
or on such Director’s or Officer’s behalf in connection with any Proceeding or any claim, issue or matter therein (other
than an action by or in the right of the Corporation), which such Director or Officer is, or is threatened to be made, a party to or
participant in by reason of such Director’s or Officer’s Corporate Status, if such Director or Officer acted in good faith
and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation and, with
respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful.
(ii)
Actions, Suits and Proceedings By or In the Right of the Corporation. Each Director and Officer shall be indemnified and
held harmless by the Corporation against any and all Expenses that are incurred by such Director or Officer or on such Director’s
or Officer’s behalf in connection with any Proceeding or any claim, issue or matter therein by or in the right of the Corporation,
which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director’s or Officer’s
Corporate Status, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in
or not opposed to the best interests of the Corporation; provided, however, that no indemnification shall be made under this Section 5(b)(2)
in respect of any claim, issue or matter as to which such Director or Officer shall have been finally adjudged by a court of competent
jurisdiction to be liable to the Corporation, unless, and only to the extent that, the Court of Chancery or another court in which such
Proceeding was brought shall determine upon application that, despite adjudication of liability, but in view of all the circumstances
of the case, such Director or Officer is fairly and reasonably entitled to indemnification for such Expenses that such court deems proper.
(iii)
Survival of Rights. The rights of indemnification provided by this Section 5(b) shall continue as to a Director or Officer
after he or she has ceased to be a Director or Officer and shall inure to the benefit of his or her heirs, executors, administrators and
personal representatives.
(iv)
Actions by Directors or Officers. Notwithstanding the foregoing, the Corporation shall indemnify any Director or Officer
seeking indemnification in connection with a Proceeding initiated by such Director or Officer only if such Proceeding (including any parts
of such Proceeding not initiated by such Director or Officer) was authorized in advance by the Board of Directors of the Corporation,
unless such Proceeding was brought to enforce such Officer’s or Director’s rights to indemnification or, in the case of Directors,
advancement of Expenses under these Bylaws in accordance with the provisions set forth herein.
(c)
Indemnification of Non-Officer Employees. Subject to the operation of Section 5(d) of these By-laws, each Non-Officer Employee
may, in the discretion of the Board of Directors of the Corporation, be indemnified by the Corporation to the fullest extent authorized
by the DGCL, as the same exists or may hereafter be amended, against any or all Expenses and Liabilities that are incurred by such Non-Officer
Employee or on such Non-Officer Employee’s behalf in connection with any threatened, pending or completed Proceeding, or any claim,
issue or matter therein, which such Non-Officer Employee is, or is threatened to be made, a party to or participant in by reason of such
Non-Officer Employee’s Corporate Status, if such Non-Officer Employee acted in good faith and in a manner such Non-Officer Employee
reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had
no reasonable cause to believe his or her conduct was unlawful. The rights of indemnification provided by this Section 5(c) shall exist
as to a Non-Officer Employee after he or she has ceased to be a Non-Officer Employee and shall inure to the benefit of his or her heirs,
personal representatives, executors and administrators. Notwithstanding the foregoing, the Corporation may indemnify any Non-Officer
Employee seeking indemnification in connection with a Proceeding initiated by such Non-Officer Employee only if such Proceeding was authorized
in advance by the Board of Directors of the Corporation.
(d)
Determination. Unless ordered by a court, no indemnification shall be provided pursuant to this Section 5 to a Director,
to an Officer or to a Non-Officer Employee unless a determination shall have been made that such person acted in good faith and in a manner
such person reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal Proceeding,
such person had no reasonable cause to believe his or her conduct was unlawful. Such determination shall be made by (a) a majority vote
of the Disinterested Directors, even though less than a quorum of the Board of Directors, (b) a committee comprised of Disinterested Directors,
such committee having been designated by a majority vote of the Disinterested Directors (even though less than a quorum), (c) if there
are no such Disinterested Directors, or if a majority of Disinterested Directors so directs, by independent legal counsel in a written
opinion, or (d) by the stockholders of the Corporation.
(e)
Advancement of Expenses to Directors Prior to Final Disposition.
(i)
The Corporation shall advance all Expenses incurred by or on behalf of any Director in connection with any Proceeding in which
such Director is involved by reason of such Director’s Corporate Status within thirty (30) days after the receipt by the Corporation
of a written statement from such Director requesting such advance or advances from time to time, whether prior to or after final disposition
of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Director and shall be preceded
or accompanied by an undertaking by or on behalf of such Director to repay any Expenses so advanced if it shall ultimately be determined
that such Director is not entitled to be indemnified against such Expenses. Notwithstanding the foregoing, the Corporation shall advance
all Expenses incurred by or on behalf of any Director seeking advancement of expenses hereunder in connection with a Proceeding initiated
by such Director only if such Proceeding (including any parts of such Proceeding not initiated by such Director) was (A) authorized by
the Board of Directors of the Corporation, or (B) brought to enforce such Director’s rights to indemnification or advancement of
Expenses under these Bylaws.
(ii)
If a claim for advancement of Expenses hereunder by a Director is not paid in full by the Corporation within thirty (30) days after
receipt by the Corporation of documentation of Expenses and the required undertaking, such Director may at any time thereafter bring suit
against the Corporation to recover the unpaid amount of the claim and if successful in whole or in part, such Director shall also be entitled
to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof,
independent legal counsel, or stockholders) to make a determination concerning the permissibility of such advancement of Expenses under
this Article V shall not be a defense to an action brought by a Director for recovery of the unpaid amount of an advancement claim and
shall not create a presumption that such advancement is not permissible. The burden of proving that a Director is not entitled to an advancement
of expenses shall be on the Corporation.
(iii)
In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation
shall be entitled to recover such expenses upon a final adjudication that the Director has not met any applicable standard for indemnification
set forth in the DGCL.
(f)
Advancement of Expenses to Officers and Non-Officer Employees Prior to Final Disposition.
(i)
The Corporation may, at the discretion of the Board of Directors of the Corporation, advance any or all Expenses incurred by or
on behalf of any Officer or any Non-Officer Employee in connection with any Proceeding in which such person is involved by reason of his
or her Corporate Status as an Officer or Non-Officer Employee upon the receipt by the Corporation of a statement or statements from such
Officer or Non-Officer Employee requesting such advance or advances from time to time, whether prior to or after final disposition of
such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Officer or Non-Officer Employee
and shall be preceded or accompanied by an undertaking by or on behalf of such person to repay any Expenses so advanced if it shall ultimately
be determined that such Officer or Non-Officer Employee is not entitled to be indemnified against such Expenses.
(ii)
In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation
shall be entitled to recover such expenses upon a final adjudication that the Officer or Non-Officer Employee has not met any applicable
standard for indemnification set forth in the DGCL.
(g)
Contractual Nature of Rights.
(i)
The provisions of this Section 5 shall be deemed to be a contract between the Corporation and each Director and Officer entitled
to the benefits hereof at any time while this Section 5 is in effect, in consideration of such person’s past or current and any
future performance of services for the Corporation. Neither amendment, repeal or modification of any provision of this Section 5 nor the
adoption of any provision of the Certificate of Incorporation inconsistent with this Section 5 shall eliminate or reduce any right conferred
by this Section 5 in respect of any act or omission occurring, or any cause of action or claim that accrues or arises or any state of
facts existing, at the time of or before such amendment, repeal, modification or adoption of an inconsistent provision (even in the case
of a proceeding based on such a state of facts that is commenced after such time), and all rights to indemnification and advancement of
Expenses granted herein or arising out of any act or omission shall vest at the time of the act or omission in question, regardless of
when or if any proceeding with respect to such act or omission is commenced. The rights to indemnification and to advancement of expenses
provided by, or granted pursuant to, this Section 5 shall continue notwithstanding that the person has ceased to be a director or officer
of the Corporation and shall inure to the benefit of the estate, heirs, executors, administrators, legatees and distributees of such person.
(ii)
If a claim for indemnification hereunder by a Director or Officer is not paid in full by the Corporation within sixty (60) days
after receipt by the Corporation of a written claim for indemnification, such Director or Officer may at any time thereafter bring suit
against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, such Director or Officer shall
also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors
or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such indemnification
under this Section 5 shall not be a defense to an action brought by a Director or Officer for recovery of the unpaid amount of an indemnification
claim and shall not create a presumption that such indemnification is not permissible. The burden of proving that a Director or Officer
is not entitled to indemnification shall be on the Corporation.
(iii)
In any suit brought by a Director or Officer to enforce a right to indemnification hereunder, it shall be a defense that such Director
or Officer has not met any applicable standard for indemnification set forth in the DGCL.
(h)
Non-Exclusivity of Rights. The rights to indemnification and advancement of Expenses set forth in this Section 5 shall not
be exclusive of any other right which any Director, Officer, or Non-Officer Employee may have or hereafter acquire under any statute,
provision of the Certificate or these By-laws, agreement, vote of stockholders or Disinterested Directors or otherwise.
(i)
Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any Director, Officer or Non-Officer
Employee against any liability of any character asserted against or incurred by the Corporation or any such Director, Officer or Non-Officer
Employee, or arising out of any such person’s Corporate Status, whether or not the Corporation would have the power to indemnify
such person against such liability under the DGCL or the provisions of this Section 5.
(j)
Other Indemnification. The Corporation’s obligation, if any, to indemnify or provide advancement of Expenses to any
person under this Section 5 as a result of such person serving, at the request of the Corporation, as a director, partner, trustee, officer,
employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced
by any amount such person may collect as indemnification or advancement of Expenses from such other corporation, partnership, joint venture,
trust, employee benefit plan or enterprise (the “Primary Indemnitor”). Any indemnification or advancement of Expenses under
this Section 5 owed by the Corporation as a result of a person serving, at the request of the Corporation, as a director, partner, trustee,
officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall
only be in excess of, and shall be secondary to, the indemnification or advancement of Expenses available from the applicable Primary
Indemnitor(s) and any applicable insurance policies.
6.
Miscellaneous Provisions
(a)
Fiscal Year. Except as otherwise determined by the Board of Directors, the fiscal year of the Corporation shall end on December
31 of each year.
(b)
Seal. The Board of Directors shall have power to adopt and alter the seal of the Corporation.
(c)
Execution of Instruments. Subject to any limitations which may be set forth in a resolution of the Board of Directors, all
deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by the Corporation in the ordinary course of
its business without director action may be executed on behalf of the Corporation by, a President, or by any other officer, employee or
agent of the Corporation as the Board of Directors may authorize.
(d)
Voting of Securities. Unless the Board of Directors otherwise provides, a President, any Vice President or the Treasurer
may waive notice of and act on behalf of this Corporation, or appoint another person or persons to act as proxy or attorney in fact for
this Corporation with or without discretionary power and/or power of substitution, at any meeting of stockholders or shareholders of any
other corporation or organization, any of whose securities are held by this Corporation.
(e)
Resident Agent. The Board of Directors may appoint a resident agent upon whom legal process may be served in any action
or proceeding against the Corporation.
(f)
Corporate Records. The original or attested copies of the Certificate of Incorporation, By-laws and records of all meetings
of the incorporators, stockholders and the Board of Directors and the stock and transfer records, which shall contain the names of all
stockholders, their record addresses and the amount of stock held by each, shall be kept at the principal office of the Corporation, at
the office of its counsel, or at an office of its transfer agent.
(g)
Certificate of Incorporation. All references in these By-laws to the Certificate of Incorporation shall be deemed to
refer to the Certificate of Incorporation of the Corporation, as amended and in effect from time to time.
(h)
Amendments. These By-laws may be altered, amended or repealed, and new By-laws may be adopted, by the stockholders
or by the Board of Directors; provided, that (a) the Board of Directors may not alter, amend or repeal any provision of these By-laws
which by law, by the Certificate of Incorporation or by these By-laws requires action by the stockholders and (b) any alteration,
amendment or repeal of these By-laws by the Board of Directors and any new By-law adopted by the Board of Directors may be altered,
amended or repealed by the stockholders.
(i)
Waiver of Notice. Whenever notice is required to be given under any provision of these By-laws, a written waiver, signed
by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the
time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute
a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of
the meeting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted
at, nor the purpose of, any meeting needs to be specified in any written waiver or any waiver by electronic transmission.
Amended and
Restated on January 26, 2024
v3.23.4
Cover
|
Jan. 26, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jan. 26, 2024
|
Current Fiscal Year End Date |
--12-31
|
Entity File Number |
001-40356
|
Entity Registrant Name |
RAIN
ONCOLOGY INC.
|
Entity Central Index Key |
0001724979
|
Entity Tax Identification Number |
82-1130967
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
8000 Jarvis Avenue
|
Entity Address, Address Line Two |
Suite 204
|
Entity Address, City or Town |
Newark
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94560
|
City Area Code |
(510)
|
Local Phone Number |
953-5559
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.001 par value per share
|
Trading Symbol |
RAIN
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Entity Information, Former Legal or Registered Name |
Not
Applicable
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Grafico Azioni Rain Oncology (NASDAQ:RAIN)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Rain Oncology (NASDAQ:RAIN)
Storico
Da Set 2023 a Set 2024